Evaluation of marker density for population stratification adjustment and of a family-informed phenotype imputation method for single variant and variant-set tests of association by Chen, Yuning
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2018
Evaluation of marker density for
population stratification adjustment
and of a family-informed
phenotype imputation method for





GRADUATE SCHOOL OF ARTS AND SCIENCES
Dissertation
EVALUATION OF MARKER DENSITY FOR POPULATION STRATIFICATION
ADJUSTMENT AND OF A FAMILY-INFORMED PHENOTYPE IMPUTATION




B.S., Beijing Institute of Technology, 2011
M.S., Marquette University, 2013
Submitted in partial fulfillment of the











Gina M. Peloso, Ph.D.
Assistant Professor of Biostatistics
Third Reader
Ching-Ti Liu, Ph.D.
Associate Professor of Biostatistics
Acknowledgments
First, I would like to express my deepest gratitude to my major advisor Dr. Josée Dupuis,
who has helped me, supported me and changed my life. Josée not only teaches me the
knowledge of statistics and genetics, but also shows me how to be a good researcher and a
good person. Josée’s advices and guidance help me move forward to get my PhD. Without
Josée, I would not have been able to finish this dissertation. I would also like to sincerely
thank my whole dissertation committee: Dr. Gina Peloso, Dr. Ching-Ti Liu, Dr. Anita
DeStefano and Dr. Kathryn Lunetta for their very helpful and invaluable advice for my
research.
I would like to thank Shuai for her tremendous help in my first two years. My friends
Yicheng and Qiang have been very supportive and I wish all of my friends a brighter
future.
Finally, I want to express my gratitude to my parents for their love and support through
my journey towards this degree.
iv
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ABSTRACT
Whole exome sequencing (WES) data cover only 1% of the genome and is designed to
capture variants in coding regions of genes. When associating genetic variations with an
outcome, there are multiple issues that could affect the association test results. This
dissertation will explore two of these issues: population stratification and missing data.
Population stratification may cause spurious association in analysis using WES data, an
issue also encountered in genome-wide association studies (GWAS) using genotyping
array data. Population stratification adjustments have been well studied with array-based
genotypes but need to be evaluated in the context of WES genotypes where a smaller
portion of the genome is covered. Secondly, sample size is a major component of
statistical power, which can be reduced by missingness in phenotypic data. While some
phenotypes are hard to collect due to cost and loss to follow-up, correlated phenotypes
v
that are easily collected and are complete can be leveraged in tests of association.
First, we compare the performance of GWAS and WES markers for population
stratification adjustments in tests of association. We evaluate two established approaches:
principal components (PCs) and mixed effects models. Our results illustrate that WES
markers are sufficient to correct for population stratification. Next, we develop a
family-informed phenotype imputation method that incorporates information contained in
family structure and correlated phenotypes. Our method has higher imputation accuracy
than methods that do not use family members and can help improve power while
achieving the correct type-I error rate. Finally, we extend the family-informed phenotype
imputation method to variant-set tests. Single variant tests do not have enough power to
identify rare variants with small effect sizes. Variant-set association tests have been
proven to be a powerful alternative approach to detect associations with rare variants. We
derive a theoretical statistical power approximation for both burden tests and Sequence
Kernel Association Test (SKAT) and investigate situations where our imputation approach
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Genome-wide association studies (GWAS) have identified thousands of single nucleotide
variants (SNVs) associated with complex traits and phenotypes [1, 2, 3]. GWAS include
SNVs covering the human genome, both within and outside of genes and regulatory
regions. However, associated variants often fall outside of genes and regulatory regions,
and do not contribute to further our understanding of the genetic architecture of a disease
because of our current, limited understanding of the function of the majority of the
genome. In order to identify causal variants, whole exome sequencing (WES) has become
one of the leading strategies in association studies because of the easy interpretability of
WES variants [10]. Exons provide a good source of variants potentially influencing
complex traits and diseases even though they only cover about 1% of the whole genome.
With the increase of collaboration among researchers all over the world, it is possible to
collect data on individuals from different ancestry so that the sample size of a study can be
maximized and statistical power can be increased. However, GWAS still suffer from two
issues that could affect the association test results: population stratification and missing
data. Population stratification, which is the allele frequency difference between cases and
controls due to ancestry difference, is a source of inflated type-I error when it is not
corrected [4]. Missing data are common in epidemiology studies due to cost and lost to
1
follow-up.
In any genetic study, information about ancestry is not always available or collected. In
addition, the collected self-reported ancestry information may not be accurate or too
broad. Including samples from different ancestries can introduce population stratification,
which can cause false-positive results. Among all methods to account for population
stratification, principal component analysis (PCA) and mixed effects models are the most
popular approaches because of their convenience and good performance in GWAS.
While many approaches have been developed for genotype imputation, little attention has
been given to phenotype imputation. The most common way to handle missing phenotype
data is remove the individuals with missing observations, which decreases the sample size
and the statistical power to detect the association, and could introduce bias if the missing
mechanism is not missing completely at random (MCAR) or missing at random (MAR).
Some phenotypes are hard to collect but related phenotypes may be available and can be
exploited. For example, a CT scan is needed to measure visceral fat. However, one can
use waist hip ratio or waist circumference as alternatives, which only requires a tape
measure. Information contained in the related phenotypes can be included in the
phenotype imputation.
In this dissertation, we focus on population stratification and missing data issues in GWAS
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and exome-wide association studies. We investigate the performance of WES variants on
population stratification adjustment approaches and compare the results from association
tests using GWAS array and WES variants to correct for population stratification. We also
develop a phenotype imputation approach that can include information contained in
related phenotypes and family structure. Lastly, we extend the phenotype imputation
method from single variant tests to variant-set tests, and investigate its performance under
different situations through extensive simulation work.
1.2 Population Stratification
1.2.1 Principal Component Analysis
Population stratification, the allele frequency difference between cases and controls due to
ancestry, can be corrected by PCA [4, 5]. PCA is a dimension reduction method that
converts possibly correlated observations into a set of linearly independent variables: the
principal components (PCs). In genetic studies, PCA can be applied to genotype data to
reduce the dimension of the data and the population stratification can be captured by the
PCs. Because the top PCs can explain most of the variability in ancestry, they can be
included as covariates in association tests to correct for population stratification. Models
without PC adjustment can result in the identification of spurious association in the
presence of population stratification.
PCA starts with computing the covariance matrix of the genotype data, and then the
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eigenvectors on this matrix are obtained. Alternatively, one can also perform singular
value decomposition (SVD) on the genotype matrix. The kth eigenvector or PC
corresponds to the kth eigenvalue λk. Each eigenvalue is proportional to the percentage of
variance explained by the corresponding eigenvector. The first PC can explain the largest
variance of the genotypic data, and each succeeding PC has the highest variance under the
constraint that it is orthogonal to the preceding PCs.
Mathematically, PCs are linear combinations of the genotype vectors. Genetic variants
with larger weight in the linear combination show bigger difference between populations
and hence contribute more in the PC computation than variants with a smaller weight.
These variants are also referred to as ancestry-informative markers (AIMs). In this
dissertation, the PC computation is done using the smartpca program in the EIGENSOFT
package [5].
1.2.2 Mixed Effects Model
A linear mixed effects model can be used to account for population stratification when the
phenotype is continuous [7]. The model can be written as y = Xβ +Zu+ e, where y is the
n×1 phenotype vector, X is the n×q matrix including covariates and the genotype of a
single variant, β is the q×1 vector of the regression coefficients of fixed effects, Z is the
n× t incidence matrix relating each item in the phenotype vector to one of the t
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subgroups, u is the t×1 random effect vector and e is the n×1 vector of residuals.
We further assume that Var(u) = σ2g K and Var(e) = σ2e I, where σ2g and σ2e are the
polygenic and environmental variance components. Random effect u is independent of the
residuals e and K is the kinship matrix describing the relationship between the t
subgroups. In GWAS, we usually assume that the random effect is the polygenic effect for
each sample, which implies that t = n and Z = I. The total phenotypic variance can be
written as Var(y) = Σ = σ2g K+σ2e I.
The parameters σ2g and σ
2
e are called the variance components, and are assumed to be
unknown. To solve the mixed model equation, the variance components must first be
estimated. Once this is done, a generalized least squares (GLS) procedure may be used to
estimate β by β̂ = (XTΣ−1X)−1XTΣ−1y.
When using linear mixed effects models to account for population stratification, the
kinship matrix K is computed from the genotype data. It is an n×n matrix with each entry
describing the relationship between each pair of individuals. In studies with known family
structure, K can also be computed from pedigree. When family structure is unknown,
there are two types of commonly-used kinship matrix: identical-by-state (IBS) and
Balding-Nichols (BN) kinship matrix [7]. IBS kinship matrix measures the proportion of
alleles IBS between each pair of individuals. In the BN kinship matrix, the genetic
5










where m is the total number of variants, xk,i is the genotype of the ith individual on the kth
variant and p̂k is the minor allele frequency (MAF) of the kth variant.
1.3 Association Test
1.3.1 Single-Variant Analysis
The standard GWAS framework includes one phenotype and association between the
phenotype and the SNVs is evaluated one SNV at a time using logistic (binary trait) or
linear (continuous trait) regression. The statistical model for the phenotype value of the ith
individual yi is f (yi) = β0 +β1gi + γ1xi, where f (yi) = yi for a quantitative phenotype and
f (yi) = logit P(yi = 1) for a binary trait. A normally-distributed error term ei with mean
zero and variance σ2 is added to the model for a quantitative phenotype. β1 is the
regression coefficient for the genotype gi and γ1 is the vector of regression coefficients for
the covariates vector xi. To test the association between gi and f (yi), a hypothesis test is
performed with the null H0 : β1 = 0.
To simplify the linear regression model, we can regress yi on xi, obtain the residuals and
use the residuals as outcome in the association test of the single variant. The model then
becomes, ri = β0 +β1gi + ei, where ri is the residual and ei is the error term. The
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maximum likelihood estimates are β̂0 = 1n1
T r and β̂1 = g
T r
gT g , where r and g are the
outcome and genotype vectors of all individuals and 1 is a vector of all ones. The
estimated standard error is σ̂ =
√
êT ê
n−2 , where ê = r− β̂01− β̂1g. The test statistic can then
be written as t = β̂1
σ̂
√
gT g. Note that gT g can be replaced by its estimation 2np(1− p),
where p is the MAF of the single variant. We can further standardize gi so that gT g = n.
Under the alternative hypothesis of association, the statistic t follows a normal distribution
with non-centrality parameter β1
σ
√
n and variance 1 [37].
Statistical power is the probability of correctly rejecting the null hypothesis. In GWAS, it
is equivalent to the probability of detecting a true association. Based on the derivation of








where Φ is the cumulative density function of the standard normal distribution and α is
the significance level in GWAS.
1.3.2 Variant-set Test
Even though GWAS have been very successful in detecting common variants associated
with complex traits or phenotypes, much of the heritability is still unexplained and few
rare genetic variants have been found to be associated with diseases thus far [27]. Single
variant tests do not have enough power to detect the association with rare variants, hence
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aggregating information from multiple rare genetic variants is an alternative in association
testing to improve power.
One class of aggregation tests is the burden test, which collapses the genotypes of rare
variants into a burden score and assesses the association between the burden score and the
phenotype. Similar to the single-variant analysis, we can write the statistical model for the
multiple variant test as, for the ith individual, f (yi) = β0 +βGi + γxi, where γ is the
vector of regression coefficients for the vector of covariates xi and β is the vector of
regression coefficients for the genotype vector Gi. The burden score can be written as
Ci = ∑
p
j=1 w jGi j, where w j is the weight for variant j. It is equivalent to testing
H0 : βc = 0 in f (yi) = β0 +βcCi + γxi.
Burden tests have the highest power when all variants in the same region have the same
direction of effect, but often most variants in the region have little or no effect on the
phenotype. In addition, there could be both protective and deleterious variants in the
region. To allow for the presence of both deleterious and protective variants, a variance
component test, sequence kernel association test (SKAT), was developed in a multiple
regression framework and uses a variance-component score test which is flexible and
computationally efficient.
SKAT is based on the same regression model as in the burden test with β = [β1, . . . ,βp],
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defined as the effect sizes of the p variants on the phenotype. The SKAT statistic can be
written as Q = (y− ȳ)T K(y− ȳ), where K = GWGT , G is the genotype matrix and W =
diag (w1, . . . ,wp) is the matrix of weights. Wu et al. [27] suggested to use
√w j = Beta(MAFj,1,25) so that rare variants have higher weights and variants with
MAF between 1% and 5% also have reasonable nonzero weights.
One big advantage of SKAT is that its test statistic can be computed using the individual
variant test statistics by Q = ∑pj=1 w jS
2
j , where S j is the individual score statistic for
testing the association between the phenotype and the individual variant j. In addition,
SKAT uses a score test, which only needs to fit the null model once and hence it can be
computationally efficient.
1.4 Dissertation Outline
In the first project, we compare the performance of GWAS and WES variants on
population stratification adjustment through simulation. Specifically, we compare the PCs,
kinship coefficients in the genetic relationship matrix (GRM) computed using GWAS and
WES variants, and association results between the PC-adjusted model and the mixed
effects model in terms of genomic control factor, type-I error rate and statistical power.
In the second project, we develop a family-informed phenotype imputation approach that
incorporates the information contained in family structure and additional correlated
9
phenotypes. We show that taking family structure into consideration when imputing can
improve imputation accuracy. Simulation studies show that our imputation approach can
improve the statistical power to detect the association while achieving the correct type-I
error rate. In addition, we also derive the approximated NCP in association tests of the
combined observed and imputed phenotype so that it is possible to compute the theoretical
power for the association testing in the study design phase. We show that the theoretical
power from our NCP derivation is very close to the empirical power from simulations, and
investigate the situations where our method can improve power.
In the third project, we extend the phenotype imputation approach to variant-set tests. We
focus on two commonly-used variant-set tests: burden test and SKAT. We first derive the
approach to compute the theoretical power for these two tests, and then verify our
derivation through simulation studies. We examine the type-I error rate and power of
jointly analyzing observed and imputed phenotype under different conditions through
extensive simulations. We also validate our findings using a real dataset from the
Framingham Heart Study (FHS).
10
Chapter 2 Evaluation of Marker Density for Population Stratification Adjustment
2.1 Introduction
Genome-wide association studies (GWAS) have been proven to be a useful tool to
discover single nucleotide variants (SNVs) associated with complex traits [1, 2, 3].
Typically, GWAS are restricted to study subjects that share the same ancestry. Population
stratification, which is the allele frequency difference between cases and controls due to
ancestry difference, occurs when there are multiple population groups within a sample.
The association test results can be affected by population stratification, which can result in
an inflated type-I error rate. Current methods for correcting population stratification
include principal components (PCs) of the genotypes [4, 5], genomic control factor [6],
linear mixed effects model (LMM) and generalized linear mixed effects model (GLMM)
using an empirical kinship matrix [7, 8] and structured association [9].
PC correction has been widely used in GWAS. Population stratification can be corrected
by including genetic PCs as covariates in a linear regression model for continuous traits or
a logistic regression model for binary traits. In contrast, in the genomic control method, an
overall inflation factor is used to adjust the association test statistic at every marker. Some
markers have a bigger difference in allele frequencies across different populations, while
some markers are less affected by population stratification. The overall inflation factor
treats all markers the same and hence it may over-adjust markers with small differentiation
across ancestral populations and under-adjust markers with strong differentiation. Yet
another approach, LMMs, utilize a variance component method to model genetic
11
relationships. The model includes an empirically estimated genetic relationship matrix
(GRM), which takes advantage of the high-density genotype information and estimates
the variance parameters under the null model assuming the effect of any given marker on
the phenotype is very small. The SNV effect is modeled as a fixed effect and a random
intercept is included to model the relatedness among study subjects. Lastly, the structured
association method adjusts for population stratification by assigning samples to
subpopulation clusters and combines the association results of each cluster. This approach
is highly sensitive to the number of subpopulation clusters and has intensive
computational cost for large data sets, such as GWAS.
These population stratification adjustment approaches are developed in the context of
GWAS, which include common markers across the whole genome. However, the
performance of these methods in association analyses has not been evaluated in studies
with WES data. Whether WES genotypes are sufficient to appropriately model population
stratification is an emerging question in studies without GWAS genotypes, when PCs and
GRM can only be computed using WES markers. Belkadi et al. [10] found a strong
correlation between PCs computed using GWAS and WES variants, and that an accurate
estimation of population stratification can be obtained using high-quality WES variants
with MAF > 2%. Gazal et al. [11] evaluated the performance of linkage analysis using
GWAS and WES variants and showed that they had similar performance in excluding
genomic regions with false-positive candidate causal variants. Smith et al. [12] also
12
demonstrated that accurate genetic linkage mapping can be performed using WES data.
Kancheva et al. [13] showed that WES variants can provide high specificity and sensitivity
for the detection of homozygous regions in consanguineous families when using GWAS
variants as reference. Eu-ahsunthornwattana et al. [14] compared kinship matrices
computed using different number of SNVs and different softwares, and found that the
kinship coefficients computed using ∼50,000 SNVs were highly correlated with those
computed using ∼545,000 SNVs.
In this chapter, we focus on the PC-based and LMM/GLMM-based population
stratification adjustment methods. There are two concerns with using WES-computed PCs
and GRM: 1) The PCs and GRM can only capture the genetic information in exons, while
PCs and GRM computed using GWAS markers are able to capture the genetic information
contained on the whole genome, hence they should be more accurate than WES-computed
PCs and GRM; and 2) because the number of markers in WES is usually smaller than that
in GWAS, the WES-computed PCs and GRM may contain less information than
GWAS-computed PCs and GRM due to the inclusion of fewer markers in the
computation. It seems obvious that the potential loss of both quality and quantity in WES
variants can lead to insufficient adjustment for population stratification.
Our goals are to compare the PCs and GRM computed using GWAS and WES variants, to
examine the effect of these two sets of PCs and GRM on association analysis results, and
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to evaluate performance of PC-based and LMM/GLMM-based methods. We use
simulations to compare the PCs and GRM computed using GWAS or WES variants in
terms of genomic control factor, type-I error rate and power in association analyses. A real
data set from the Framingham Heart Study (FHS) is used to compare the association




We use the genotypes from the 1000 Genome Project Phase 3 [15] dataset. GWAS
variants are selected based on Illumina HumanHap300K BeadChip which is designed
using international HapMap Project [19] data of individuals from CEU [20]. WES
markers are annotated using the EPACTS [21] Version 3.2.6 annotation function based on
GENCODE V7 transcripts. We first apply the following quality control (QC) filters on all
selected GWAS and WES SNVs in the 1000G dataset: MAF ≥ 1%, call rate ≥ 99%,
Hardy-Weinberg Equilibrium P-value > 0.0001. Variants passing these QC filters are used
for evaluation of the type-I error rate. We then select a subset of these SNVs for PCs and
GRM computation based on the additional QC criterion: minor allele frequency ≥ 5% and
only one SNV of each pair of SNVs with LD r2 > 0.5 in a 50 SNVs window.
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2.2.2 PCs and GRM Computation
PCs and two types of GRM, IBS and BN kinship matrix [14] are computed using three
sets of variants: 1) GWAS variants; 2) WES variants; and 3) a randomly selected subset of
GWAS variants that has the same number of variants as the WES set. The inclusion of the
third set of variants above is to eliminate the difference in the number of variants used in
PCs and GRM calculation. All PCs and GRM are computed using EIGENSTRAT [4] and
EMMAX [7], respectively.
2.2.3 Simulation Study Subjects
We select founders from the 1000G Phase 3 data set to generate simulated data. European
ancestry (EA) founders are from 5 cohorts: FIN (Finnish in Finland), CEU (Utah
Residents with Northern and Western Ancestry), GBR (British in England and Scotland),
IBS (Iberian Population in Spain) and TSI (Toscani in Italy). African ancestry (AA)
founders are from 7 cohorts: ASW (Americans of African Ancestry in SW USA), ACB
(African Caribbeans in Barbados), LWK (Luhya in Webuye, Kenya), ESN (Esan in
Nigeria), GWD (Gambian in Western Divisions in the Gambia), MSL (Mende in Sierra
Leone) and YRI (Yoruba in Ibadan, Nigeria). We then compute PCs on two sets of study
subjects: 1) using both EA and AA founders; and 2) restricting our analysis to EA
founders only to generate a dataset with more subtle ancestry differences between
sub-populations. Based on the clustering pattern (Figure 2.1), we divide the combined EA
and AA 1000G founders into 6 groups (group 1, FIN; group 2, CEU, GBR; group 3, IBS,
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TSI; group 4, ASW, ACB; group 5, LWK; group 6: ESN, GWD, MSI, YRI), while we do
not combine cohorts in the analysis restricted to EA founders, so we simply refer to FIN,
CEU, GBR, IBS and TSI as groups 1-5, respectively. Next, within each group, we
generate genotypes for 333 simulated individuals for the combined EA and AA analysis
and 400 for EA only analysis while maintaining the same linkage disequilibrium (LD)
pattern as observed in each population between variants using the software Hapgen2 [16].
In total, 1998 and 2000 individuals are generated for the EA and AA, and EA only
analyses, respectively.
2.2.4 Comparison of PCs and GRM Generated Using GWAS and WES Variants
To compare PCs, we first consider a plane developed by the first 2 PCs as they explain
most of the variance. A centroid is defined by the mean vector of the first 2 PCs for each
sub-group. Then the Euclidean distance from the group-specific centroid to each
simulated sample is computed and a Wilcoxon signed-rank test is performed to compare
the distance difference computed using GWAS variants, WES variants and the subset of
GWAS variants which has the same number of variants as the WES set. In order to
compare GRMs, we compute the Pearson correlation between the kinship coefficients
contained in the GRM.
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Figure 2.1: Population stratification in 1000G Phase 3 data.
Top left panel: scatterplot of PC1 vs. PC2 computed using GWAS markers in the
combined EA and AA analysis. Top right panel: scatterplot of PC1 vs. PC2 computed
using GWAS markers in the EA only analysis. Bottom left panel: scatterplot of PC1 vs.
PC3 computed using WES markers in the combined EA and AA analysis. Bottom right
panel: scatterplot of PC1 vs. PC2 computed using WES markers in the EA only analysis.
The grouping in EA and AA founders is: group 1, FIN; group 2, CEU, GBR; group 3, IBS,
TSI; group 4, ASW, ACB; group 5, LWK; group 6: ESN, GWD, MSI, YRI. The grouping
in EA samples is: group 1, FIN; group 2, CEU; group3, GBR; group 4, IBS; group 5, TSI.
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2.2.5 Comparison of Genomic Control Factor and Type-I Error Rate
To examine genomic control factor, λGC, defined as the ratio of the median observed test
statistic to the expected test statistic under the null hypothesis, and type-I error rate, the
continuous phenotype values are assigned based on a pre-specified group-specific mean
level. A random error term which follows a normal distribution is then added to the
assigned mean levels. In the test of a binary outcome, a total of 999 or 1000 randomly
selected cases are generated for EA and AA, and EA only data, respectively. The
prevalences of the simulated disease are set to 2%, 5%, 8%, 10%, 15% and 18% for the 6
EA and AA groups, while they are 2%, 5%, 8%, 10% and 15% for the 5 EA groups. The
continuous and binary phenotypes are not associated with any simulated SNVs. We
perform association analyses on all GWAS and WES variants with MAF ≥ 1% in spite of
whether or not they are included in the PC calculation to mimic the GWAS in practice.
Variants with MAF < 1% are not included due to low statistical power to detect
association with low-frequency SNVs in actual GWAS. PCs and GRM computed using
GWAS and WES markers are used for population stratification adjustment.
Four linear/logistic regression models are performed: 1) Y ∼ SNV, an unadjusted model;
2) Y ∼ SNV + Group, a model adjusted for the true grouping assignment, which is used
as the gold standard; 3) Y ∼ SNV + PCsGWAS, a model adjusted for first 10 PCs computed
from GWAS variants; and 4) Y ∼ SNV + PCsWES, a model adjusted for the first 10 PCs
computed from WES variants. Besides these four models, two LMMs for continuous trait
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and two GLMMs for binary trait, using GWAS-computed and WES-computed empirical
kinship matrix to account for population stratification, respectively, are also performed. In
addition, for binary traits, we also include PCs in the GLMM-based method to evaluate
the performance of using both PCs and GRM to adjust for population stratification. The
association analyses are performed using PLINK [22] for PC-adjusted models, EMMAX
[7] and the R package GENESIS [8] for mixed effects models of continuous and binary
traits, respectively, and repeated 500 times.
2.2.6 Power Evaluation
To evaluate power, we select 10 SNVs to be associated with the phenotype. Five of the 10
SNVs (rs2239923, rs17639812, rs3739555, rs4556520 and rs2124147 for EA and AA
analysis; rs3783501, rs3741190, rs9559516, rs2071593 and rs764231 for EA only
analysis) are confounded by population stratification, as indicated with a high PC weight
for PC1 or PC2, and the other 5 SNVs (rs4736111, rs2238740, rs7221974, rs2071624 and
rs793878 for EA and AA analysis; rs1047406, rs2276232, rs3745009, rs161557 and
rs3746619 for EA only analysis) are not confounded, with low PC weights for PC1 and
PC2. To select the 10 SNVs, we first rank the absolute value of the weights of the first 2
PCs in GWAS and WES sets separately for each SNV present in both GWAS and WES
set. Then the ranks are added up and the top 5 SNVs (high weight, confounded by
population stratification) and the last 5 SNVs (low weight, not confounded by population
stratification) are selected to generate simulated phenotypes. By assuming the percentage
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of the phenotypic variance explained by the SNV as R2 = 1%, the effect size β is set to be
equal in all studies and it is computed using β =
√
R2
2p(1−p) , where p is the MAF obtained
in all studies. A normally distributed random error term is added to the linear combination
of β ’s and genotypes, with a group-specific mean and variance 1. The associated binary
trait is then generated by assigning samples whose continuous trait value is above the 90%
percentile of all samples as cases to achieve a 10% population prevalence. We evaluate the
same models used in type-I error rate evaluation at α level of 10−4. The association
analyses are performed using PLINK [22] for PC-adjusted models, EMMAX [7] and the
R package GENESIS [8] for mixed effects models of continuous and binary traits,
respectively, and repeated 500 times.
2.2.7 Comparison Using FHS GWAS and Exome Chip Data
In 1948, FHS enrolled its first participants, the Original Cohort with 5,209 individuals,
from Framingham, MA. These participants aged between 30 and 62 underwent detailed
physical examination, lifestyle interviews and laboratory tests every two years to discover
the risk factors of cardiovascular disease (CVD). The Offspring cohort of 5,124
participants was recruited in 1971. These individuals consist of the children and spouses
of the children of the Original Cohort participants and attend the physical exams
approximately every four years. The third generation (Gen3) Cohort, which consists of the
grandchildren of the Original Cohort was enrolled in 2002. Till today, 32 exams have been
performed in the Original Cohort, while 9 and 2 exams have been performed in the
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Offspring and Gen3 Cohorts.
We perform a comparison using FHS GWAS and exome chip data with height as the
outcome. Height was collected in exam 1 for all individuals in the three cohorts. FHS
participants in the SNP Health Association Resource (SHARe) were genotyped using the
Affymetrix 500K + 50K MIPS chip. We use these variants as the GWAS variants. As part
of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium, exome chip variants were genotyped with the Illumina HumanExome
BeadChip [18]. The same filtering criteria are used to select variants for the PCs and
GRMs computation: MAF ≥ 5%, call rate ≥ 99%, Hardy-Weinberg Equilibrium P-value
> 0.0001 and only one SNV of each pair of SNVs with LD r2 > 0.5 in a 50 SNVs window.
Unrelated individuals are selected based on known pedigree structures to compute the
weight of each SNV on PCs, then PCs are projected on related participants [24]. We test
the association between the residual of height computed with adjustment for sex, age, age2
and cohort indicator and SNV rs2322659, which is known for its spurious association with
height due to population stratification. Two linear regression models, Y ∼ SNV +
PCsGWAS and Y ∼ SNV + PCswes, and two mixed effects models using GWAS-computed
or exome chip-computed IBS kinship matrix, respectively, are performed with adjustment
for the first 10 PCs. We then compare the effect size estimate and P-value for each model.
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Table 2.1: Origin of 1000G EA and AA founders
EA population N AA population N
FIN 99 ASW 61
CEU 95 ACB 96
GBR 90 LWK 97
IBS 107 ESN 99




We select 498 unrelated EA individuals originating from 5 populations and 657 unrelated
AA individuals originating from 7 populations in 1000G Phase 3 data set (Table 2.1). A
total of 439,601 SNVs with MAF ≥ 1% for EA and AA, and 516,250 for EA only, pass
the QC filters for type-I error evaluation. Among 439,601 SNVs in the EA and AA
analysis, 180,472 SNVs in the GWAS set and 66,166 SNVs in the WES set pass the
additional filtering criteria for PCs and GRM calculation. A total of 172,330 SNVs in the
GWAS set and 57,584 SNVs in the WES set are included to compute PCs and GRM in the
EA only analysis. A PC analysis restricted to unrelated 1000G EA and AA individuals,
and EA individuals alone, is performed before we generate the simulated genotypes.
Based on the clustering pattern in PCA, we divide the combined EA and AA, and EA
samples alone, into 6 and 5 groups, respectively. Using the genotypes from 498 unrelated
EA and 657 unrelated AA samples, 1,998 (333 × 6 groups) EA and 2,000 (400 × 5
groups) AA simulated samples are generated in each iteration of the simulation.
The Wilcoxon signed-rank test is performed on the Euclidean distance from the
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group-specific centroid to each simulated sample. We make a pairwise comparison on
distance difference computed using GWAS variants, WES variants and a randomly
selected subset of GWAS variants which has the same number of variants as the WES set.
Among 500 iterations, P-values of the Wilcoxon signed-rank test when comparing GWAS
variants with WES variants and the randomly selected subset of GWAS variants are highly
significant. P-values are 2.9 ×10−12 and 1.6 ×10−17 in the EA + AA dataset, and 2.1
×10−4 and 0.01 in the EA only dataset, for the difference between GWAS and EC and
GWAS and Random, respectively, which indicates that GWAS-computed PCs are
significantly different from both WES-computed PCs and PCs computed using the subset
of GWAS variants. However, only 100 iterations for EA + AA analysis and 26 for EA
only analysis have P-value < 0.05 when comparing WES-computed PCs with PCs
computed using the subset of GWAS variants, and 35 iterations for EA + AA analysis and
5 for EA only analysis have P-value < 0.01. These results show that the differences
between GWAS-computed and WES-computed PCs are mainly due to the number of
variants included in the calculation.
In the comparison of kinship coefficients, Pearson correlations (Figure 2.2) show that
kinship measures computed using GWAS and WES variants are highly correlated when
there are only EA samples. In the presence of EA and AA samples, the correlation
between WES and GWAS of the randomly selected set of GWAS markers is ∼ 0.77 in the
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IBS kinship matrix, while it is above 0.9 in the BN kinship matrix.
Figure 2.2: Pair-wise comparison of kinship coefficients computed using GWAS and WES
variants
Left: kinship coefficients in the combined EA and AA samples. Right: kinship
coefficients in EA samples only. Plots above the diagonal are the scatterplots of the
kinship coefficients. Plots below the diagonal are the Pearson correlations between them.
GWAS IBS and GWAS BN represent the IBS and BN kinship matrix with GWAS
markers, WES IBS and WES BN are the IBS and BN kinship matrix with WES markers,
GWAS2 IBS and GWAS2 BN indicate the IBS and BN kinship matrix computed using a
randomly selected subset of GWAS markers that has the same number of markers as the
WES set
In both the EA + AA and EA only dataset, the genomic control factor λGC of unadjusted
model Y ∼ SNV indicates that there is population stratification present in the data, while
in PC-adjusted models and LMM/GLMM-based methods, λGC falls within an acceptable
range except in GLMMs using IBS kinship matrix alone (binary trait)(Table 2.2). This
indicates that PCs and BN GRM computed using either GWAS or WES variants can
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correct the population stratification in the data.
We use 439,601 SNVs (EA+AA) and 516,250 SNVs (EA only) in each iteration and
repeat 500 times for a total of 219,800,500 (EA+AA) and 258,125,000 (EA only)
unassociated SNVs in order to examine type-I error rate. For the continuous trait, we
assign a pre-specified group-specific mean level, which is not associated with any
simulated SNVs, plus a normally distributed random error term to each simulated
individual. For the binary trait, we randomly select 999 cases and 999 controls (EA+AA),
or 1000 cases and 1000 controls (EA only) among all individuals in simulation. In order
to achieve the assumed population prevalence, we assume different prevalences across the
subpopulations and select 34, 86, 138, 172, 259 and 310 cases out of 333 simulated
samples in each of the 6 EA+AA group, and 50, 125, 200, 250, 375 cases out of 400
simulated samples in each of the 5 EA only group.
Type-I error rate is computed under 4 different significance levels: 0.05, 10−3, 10−4 and
10−6 (Table 2.3). For the binary outcome, there is a deflation in type-I error rate in all
models except the unadjusted model and GLMMs using the IBS kinship matrix alone.
However, the two PC-adjusted models, two GLMMs using BN kinship matrix and four
GLMMs using both GRM and PC adjustments have similar type-I error rate as the gold
standard model, which shows that they can also correctly control the type-I error. For the
continuous outcome, the PC-adjusted models correctly control type-I error. In LMMs,













































































































































































































































































































































































































































































































































































































































































using GWAS markers. While the relative type-I error rates of both the GWAS- and
WES-computed GRMs fall in an acceptable range at significance level 0.05, 10−3 and
10−4, there is a small inflation in WES-computed GRM when the threshold is 10−6. The
extent of inflation in the EA + AA analysis is less than that in the EA only analysis, which
indicates that the GRM may not be sufficient to correct type-I error when the population
stratification is more subtle. In either binary or continuous outcome, models including
PCs computed using GWAS or WES variants do not show different type-I error rate.
Power is evaluated using 10 SNVs that are associated with the simulated continuous or
binary phenotypes. In GLMMs for binary outcome, we focus on the models using the BN
kinship matrix due to the inflated type-I error rate found in models with the IBS kinship
matrix. We first compare power of using GWAS-computed PCs/GRM vs. WES-computed
PCs/GRM. The empirical power evaluations are very similar in the PC- or
LMM/GLMM-based methods between using GWAS-computed PCs/GRM and
WES-computed PCs/GRM. Then we evaluate the performance of the PC- and
LMM/GLMM-based methods between testing SNVs confounded and not confounded by
population stratification. In PC-based models and GLMMs with PC adjustment, SNVs 1-5
(low weight, not confounded by population stratification) have higher power than SNVs
6-10 (high weight, confounded by population stratification) in general. This is exactly the
result we expect because high weight SNVs contribute more to PCs than low weight

























































































































































































































































































































































































































































































































































































































































































































































weight SNVs, which in turn decreases power in association tests. In GLMMs using GRM
alone (binary outcome), high weight SNVs achieve higher power than low weight SNVs.
In LMMs (continuous outcome), high weight SNVs also have higher power when there
are EA samples only, while low weight SNVs have higher power in the simulation of EA
and AA samples. Finally, we directly compare the performance of PC-based vs.
LMM/GLMM-based methods. For SNVs 6-10, LMMs and GLMMs using GRM alone
outperform PC-based models in either the analysis with EA and AA individuals or the
analysis restricted to EA individuals. For SNVs 1-5, PC-based models and LMMs have
similar power in general when the phenotype is continuous. They also have comparable
performance in the analysis including EA and AA samples when the phenotype is binary
and a slightly higher power is achieved in PC-based models with EA samples only. In
addition, GLMMs using both GRM and PC adjustment have similar power to the
PC-based models for binary outcome.
In the application of FHS data, a subset of 122,233 SNVs in the GWAS set and 18,107
SNVs in the exome chip set pass the filtering criteria. A total of 2,464 unrelated
individuals are selected to compute PC weights based on the known pedigree structure.
The association analyses include 7,269 individuals in total. P-values in the unadjusted
model and LMM with a kinship matrix computed using the pedigree are 1.6×10−15 and
0.03 respectively, which indicates SNV rs2322659 is strongly associated with height.























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.6: Association test results from FHS
Model β SE P-value
Height∼SNV -0.1343 0.017 1.6×10−15
Height∼SNV+Kinpedigree 0.0893 0.042 0.03
Height∼SNV+Kinpedigree+PCsGWAS 0.0031 0.046 0.95
Height∼SNV+Kinpedigree+PCsEC -0.0019 0.046 0.97
Height∼SNV+KinGWAS 0.0220 0.020 0.27
Height∼SNV+KinEC 0.0248 0.019 0.19
kinship matrix (Table 2.6). This confirms that the spurious association in the unadjusted
model is due to population stratification. P-values of the PC-adjusted models and LMMs
using an empirical kinship matrix are all above 0.05, which shows that the adjustment
using exome chip variants can also alleviate the spurious association due to population
stratification in practice.
2.4 Discussion
This paper sought to compare PCs and GRM computed using GWAS and WES markers,
and to evaluate model performance of PC-based and LMM/GLMM-based methods in
terms of type-I error rate and power in association tests. Intuitively, in studies with WES
data, adjustment for potential population stratification may not be achieved because WES
markers only contain ancestry information within the exome. WES-computed PCs and
GRM may not be able to capture all useful information available in whole genome data.
Besides this concern, the fewer number of WES variants may also lead to insufficient
adjustment of population stratification because the best ancestry estimates are usually
obtained using a very large number of random markers [24]. However, our simulation and
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real data example showed that WES markers can achieve a similar performance as GWAS
markers for population stratification adjustment.
Through the comparison between PCs computed from GWAS and WES markers, we
found that the significant P-value in Wilcoxon signed rank test was due to the difference in
the number of GWAS and WES variants included in PCA. When we used the same
number of GWAS and WES variants to compute PCs, the difference disappeared.
Comparison among kinship demonstrated that the BN GRM showed consistent high
correlation (∼ 0.99) between GWAS and WES markers, while GWAS- and
WES-computed IBS GRMs were less correlated (∼ 0.76). It suggests that the WES GRM
may not perform as well as the GWAS GRM in association testing, which was verified in
our type-I error and power simulations.
Genomic control factor is often used to examine the inflation in the middle of the null
distribution, while type-I error rate is used to examine the tail of it. We compared both
quantities through simulation and drew different conclusions about the ancestry
adjustment using WES variants. The genomic control factor showed no evidence of
population stratification in models using either GWAS- or WES-computed PCs or GRM
(except IBS GRM in binary trait). However, a slightly inflated type-I error rate was found
in LMMs (continuous trait) with WES-computed GRM at a 10−6 significance level. In
contrast to the WES-computed GRM, the GWAS-computed GRM showed no inflated
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type-I error rate and had similar performance as the PC-adjusted models in these two
quantities. These results reflect the medium level of correlation (∼ 0.76) between GWAS-
and WES-computed kinship coefficients.
Our power evaluation was conducted using 5 SNVs that were confounded by population
stratification and 5 SNVs that were not confounded by stratification. The power of using
WES-computed PCs/GRM was very close to GWAS-computed PCs/GRM, which
indicates that it is appropriate to use WES data to detect SNVs with true effect.
PC-adjusted models had higher power for SNVs not confounded by population
stratification and lower power for SNVs confounded by population stratification. High
weight SNVs contributed more to PCs than low weight SNVs and hence PCs can explain
part of the phenotypic variance when testing high weight SNVs, which in turn decreases
the power in association analyses. A similar result was also found in LMMs in the
presence of EA and AA individuals, which is consistent with the previous findings that the
candidate marker should not be included in the GRM due to a potential loss of power [25].
LMMs had similar power as PC-based models in tests of low weight SNVs and higher
power when testing high weight SNVs. Hence, LMMs are more appropriate in association
analyses due to their better performance on high weight SNVs when the phenotype is
continuous. For the binary outcome, GLMMs performed better when testing high weight
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SNVs.
Another interesting finding is that the number of variants included in PCA determines the
size of the clustering. When more SNVs are included in PC computation, the Euclidean
distance between PCs of two individuals sharing the same ancestry becomes smaller,
while the distance between two samples from different ancestry becomes larger.
Although using GWAS variants to compute PCs should be the preferred approach because
it captures variation over the whole genome, WES-computed PCs are sufficient to control
inflated type-I error due to population stratification and provide similar power to
approaches adjusting for GWAS-computed PCs. For the continuous phenotype, LMMs
should be preferred over PC-adjusted models because they perform better if associated
SNVs are confounded with population stratification, such as SNVs in the HLA regions,
which are associated with many auto-immune traits but also show signs of population
stratification.
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Chapter 3 A Family-Informed Phenotype Imputation Approach
3.1 Introduction
GWAS have been very successful in detecting SNVs associated with complex traits. The
power of GWAS is limited by the number of individuals with data available for the trait of
interest. For easily measured traits, tens of thousands of individuals are typically
contributing to GWAS. However, a lack of statistical power can still occur because of
missingness in phenotypic data. Some phenotypes are difficult to collect due to cost, loss
to follow-up and inaccessibility of the biological sample at the time of the study.
Removing the samples with missing data will decrease sample size and may introduce
bias. However, with the increased use of joint analysis of multiple phenotypes and
Phenome-wide association studies (PheWAS) [36], it has become possible to collect a
large dataset on many correlated phenotypes so that the effect of missing data on one
particular phenotype can be minimized by utilizing additional correlated phenotypes. In
addition, for studies with family data, relatives are also a good source of information for
missing values on heritable traits and should be leveraged in the phenotype imputation
process.
Multivariate normal (MVN) distribution has been widely used in modeling the distribution
of the observed and missing data. A conditional MVN distribution (imputed values
conditioning on observed values) can then be obtained to generate imputed values. Price
et al. [35] imputed the Z statistic of untyped marker in an association test by exploiting the
Z statistic of typed markers and the linkage disequilibrium (LD) pattern between them
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through a conditional MVN distribution. They showed that their method can recover 84%
of the effective sample size for common variants (MAF > 5%) and 54% for rare variants
(1% < MAF < 5%). PhenIMP [37] is a phenotype imputation approach developed for
GWAS with unrelated samples. PhenIMP uses the correlation between phenotypes to
impute the missing phenotype values which are assumed to follow a conditional MVN
distribution given observed values. The pair-wise correlation matrix between phenotypes
is estimated from a pilot dataset prior to the analysis. Yet another Bayesian approach
PHENIX [38] also assumes that the approximate posterior distribution of the missing
values has the form of a MVN distribution. PHENIX treats all missing phenotype values
as parameters in a Bayesian mixed model to derive the posterior distribution of the
parameters using a Variational Bayes (VB) approach.
We propose a new family-informed phenotype imputation method which uses the
polygenic and environmental variance components of the phenotypes and the family
structure of the samples. Missing values are imputed from three pieces of information:
correlated phenotype values of the missing individual, missing phenotype values of the
missing individual’s relatives and the correlated phenotype values of these relatives. Our
method can be applied not only in studies with family data, but also in population-based
studies by using an empirical kinship matrix to account for cryptic relatedness.
In this paper, we first propose a family-informed phenotype imputation approach which
37
utilizes family structure and additional correlated phenotypes. We show that the
imputation accuracy can be improved by including family structure in the imputation. We
then explore several features of PhenIMP for studies with unrelated samples. We used
extensive simulations to evaluate the performance of our family-informed method and
verify our conclusions about PhenIMP. Specifically, we identify the situations where
imputation can boost power in an association test and situations where imputation does
not result in a gain in power, which should be very helpful when designing a study.
3.2 Methods
3.2.1 Phenotype Imputation for Family Data
Assume K phenotypes are collected on n individuals and missingness can occur in any of
the K phenotypes. Let Yk be a vector of length n to represent values of the kth phenotype
and Y=(Y1, . . . ,YK)T . We assume that the phenotype vector Y follows a MVN distribution.
The expectation vector of Y is µ = (µ1, . . . ,µK)T , where µk is the vector with each
element being the mean of phenotype k. We partition the unconditional covariance of Y
into the polygenic variance component and the environmental variance component as
Σ = ΣA⊗Φ+ΣE ⊗ I, where ⊗ represents the Kronecker product of two matrices and
ΣA =

σ2A11 σA12 · · · σA1K
σA12 σ
2
A22 · · · σA2K
...
... . . .
...




σ2E11 σE12 · · · σE1K
σE12 σ
2
E22 · · · σE2K
...
... . . .
...




Let σ2Akk and σ
2
Ekk indicate the polygenic and environmental variance of phenotype k,
respectively, and σAkl and σEkl indicate the polygenic and environmental covariance
between phenotypes k and l, respectively. All of these quantities can be estimated using
the maximum likelihood estimator (MLE) as implemented in the SOLAR software [23].
The kinship matrix Φ describes the coefficient of relationship between two individuals. It
can be derived using pedigree structure in family studies or empirically estimated using










where, Ym is the vector of all missing values in the phenotype vector Y (missing data) and
Yo is the vector of all remaining elements (observed data). The parameters µm and µo are
the corresponding vectors of the expectation µ and Σmm, Σmo, Σom and Σoo are the
corresponding block matrices of Σ.
The conditional distribution of Ym|Yo follows a MVN distribution, where the mean is
computed as
E(Ym|Yo) = µm +ΣmoΣ−1oo (Yo−µo) (3.3)
To estimate E(Ym|Yo), we use the sample mean of the observed data to estimate µm and
µo, and the MLE of the polygenic and environmental variance of the phenotypes along
with the kinship matrix to estimate Σmo and Σoo. We then use the estimated E(Ym|Yo) as
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the imputed values for the missing data in all phenotypes. The second term in the above
equation shows that the imputed value depends on the family structure of the missing
sample, expressed by ΣmoΣ−1oo , and the observed phenotypes of the missing sample and the
relatives by Yo−µo.
3.2.2 Phenotype Imputation for Population-Based Studies
In a population-based study, we can assume that the individuals are unrelated, that is
Φ = I. The above polygenic model can therefore be simplified, which is equivalent to the
approach implemented in PhenIMP. We use yk,i to represent the ith element in vector Yk.












σ211 σ12 · · · σ1K
σ12 σ
2
22 · · · σ2K
...
... . . .
...
σK1 σK2 · · · σ2KK

), (3.4)
where µk,i is the ith element of µk (mean of phenotype k), σ2kk is the variance of phenotype
k and σkl is the covariance between phenotype k and l. Similarly, we can move all the












and the imputed values are estimated E(Ym|Yo) = µm +ΣmoΣ−1oo (Yo−µo).
3.2.3 Relationship with Imputation Using Regression Model
For simplicity, consider the samples are unrelated and missingness only occurs in
phenotype 1, that is, Y1 is observed for the first n(1− r) elements and missing for the last
nr elements, where r is the percentage of missing data, and Y2, . . . ,YK are complete. In
imputation using a regression model, a regression model with Y1 as the dependent variable
and Y2, . . . ,YK as the independent variable is fitted using the n(1− r) samples with
complete information, then the nr missing values on phenotype 1 are imputed using
predictions from the estimated regression model by plugging in the corresponding
elements from Y2, . . . ,YK .
Therefore, from conditional mean imputation, the estimated regression coefficients
(without intercept) are
β̂ = (X T X )−1X T Y (3.6)
where Xn(1−r)×(K−1) =

y2,1− ȳ2 y3,1− ȳ3 · · · yK,1− ȳK
y2,2− ȳ2 y3,2− ȳ3 · · · yK,2− ȳK
... . . .
...












For i = n(1− r)+1, . . . ,n, the imputed values of phenotype 1 from imputation using a
regression model are
y1,i = ȳ1 + β̂ T (y2,i− ȳ2,y3,i− ȳ3, . . . ,yK,i− ȳK)T (3.7)
The imputed values from PhenIMP are
y1,i = ȳ1 +ΣmoΣ−1oo (y2,i− ȳ2,y3,i− ȳ3, . . . ,yK,i− ȳK)T (3.8)
where Σmo = (cov(y1,y2),cov(y1,y3), · · · ,cov(y1,yK)) and
Σoo =

cov(y2,y2) cov(y2,y3) · · · cov(y2,yK)
cov(y3,y2) cov(y3,y3) · · · cov(y3,yK)
... . . .
...
cov(yK,y2) cov(yK,y3) · · · cov(yK,yK)

Note that nΣoo = X T X and nΣmo = Y T X when n is large. We have
β̂ T = Y T X (X T X )−1 = ΣmoΣ−1oo , hence PhenIMP is equilvalent to imputation using a
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regression model.
3.2.4 Power of Single Variant Test
To compute the theoretical statistical power for a population-based GWAS, we derive the
non-centrality parameter (NCP) for the test statistic in a single variant association test
(linear regression) using the imputed phenotype, without assuming the noisy measurement
model (NMM), which was introduced in Hormozdiari et al. [37]. Without loss of
generality, we assume that all covariates are already adjusted using a linear regression
model and the residuals are used in the imputation and association test. We also center the
residuals so they have mean 0.
In NMM, phenotype 1 is assumed to have the strongest association with the SNV tested.
Other phenotypes driven by a smaller genetic effect can then be modeled as phenotype 1
plus noise. We assume phenotype k is one of these phenotypes. When testing the effect of
the SNV on phenotype 1, the test statistic can be written as s1 ∼ N(β1σ1
√
n,1), as
introduced in Chapter 1. Under NMM, the test statistic of phenotype k can then be written
as sk ∼ N(r1k β1σ1
√
k,1), where r1k is the correlation between phenotypes 1 and k. In
phenotype imputation, the imputed phenotype values can be considered as the unobserved
true phenotype values plus noise. Hence, the NCP of the test statistic for the imputed
phenotype can be approximated by the product of the NCP of the test statistic for the
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unobserved true phenotype and the correlation between the imputed and true phenotypes.
NCP is the expectation of the test statistic, hence when we perform association testing on








where p is the coded allele frequency of the SNV tested and σ2 is the variance of




oo Σom, where β̂k represents the estimated effect size of the kth phenotype.











where βk is the true effect size of the SNV on phenotype k.
3.2.5 Analysis with Combined Observed and Imputed Data
Besides performing an association test on imputed data only, it might be desirable to
analyze the observed data along with the imputed data to maximize the sample size and
hence improve power of the test. Hormozdiari et al. [37] proposed to use Stouffer’s signed
Z-score method to meta-analyze the observed and imputed data, with an optimal weight to
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account for the imputation accuracy. However, the Stouffer’s signed Z-score method does
not provide a pooled effect size estimate. Because the individual level data are available, it
is possible to perform an association test on the pooled data set. We compare these two
ways of combining the observed and imputed data, and compute the NCP to approximate
statistic power theoretically.






and simp are the test statistics from the observed and imputed data, respectively,
wobs =
√
n(1− r) and wimp =
√
nr are the weights for each test statistic, which are the
square root of the sample sizes. Hormozdiari et al. [37] proposed an optimal weight to
achieve the maximum NCP: wobs =
√





the NCP of Stouffer’s signed Z-score method is
NCPmeta =
(1− r)β1/σ1 + rΣmoΣ−1oo (β2, . . . ,βK)T√
(1− r)+ rΣmoΣ−1oo Σom
√
2p(1− p)n (3.11)
Next, to compute the test statistic of the pooled data, we can show that
E(β̂ ) = (1− r)β1 + rΣmoΣ−1oo (β2, . . . ,βK)T and σ2 = (1− r)σ21 + rΣmoΣ−1oo Σom, where βk
is the effect size of the SNV on the kth phenotype and σ21 is the variance of the first
phenotype on all observed samples. Hence, the NCP of the single variant test using both
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the combined observed and imputed samples is computed as
NCPpooled =
(1− r)β1 + rΣmoΣ−1oo (β2, . . . ,βK)T√





Comparing NCPmeta with NCPpooled , we can see that these two approaches are identical
when σ21 = 1, which means the data are standardized.
3.2.6 Strategy to Analyze the Observed and Imputed Data
In the imputed dataset, the expected value of the effect size in the pooled analysis is
ΣmoΣ
−1
oo (β2, . . . ,βK)
T , which is most likely to be different from the true effect size β1, and
the variance of the imputed data is ΣmoΣ−1oo Σom. Hence, the expected value of the
regression coefficient of the combined observed and imputed data,
(1− r)β1 + rΣmoΣ−1oo (β2, . . . ,βK)T , is biased and its estimate can not be used as an
inference of the true SNV effect β1. In addition, GWAS results often suffer from
“winner’s curse”, a phenomenon where the estimate of the genetic effect tends to have an
upward bias, which requires a replication study to estimate the true effect size. We
recommend to use the P-value from the association analysis of the combined observed and
imputed data as the final P-value of the SNV and use the effect size estimate from the
analysis of the observed data alone as the inference of the SNV effect. Therefore, we can
achieve an improved P-value and an estimate of the effect size which is not biased due to
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the imputation.
3.2.7 Factors Influencing Imputation Accuracy
We consider using the correlation and mean square error (MSE) between the imputed and
the true unobserved phenotype values as measures of imputation accuracy. Specifically,





cov(y1,i, ȳ1 +ΣmoΣ−1oo (y2,i− ȳ2, . . . ,yK,i− ȳK)T )√
1 ·ΣmoΣ−1oo Σom
=

























[(y1,i− ȳ1)2 +(ΣmoΣ−1oo (y2,i− ȳ2, . . . ,yK,i− ȳK)T )2
−2(y1,i− ȳ1)ΣmoΣ−1oo (y2,i− ȳ2, . . . ,yK,i− ȳK)T ]/nr
= var(y1)+ΣmoΣ−1oo ΣooΣ
−1
oo Σom−2ΣmoΣ−1oo (cov(y1,y2), · · · ,cov(y1,yK))T
= var(y1)−ΣmoΣ−1oo Σom
(3.14)
The above derivation shows that the MSE is determined by the variance and covariance of
the K collected phenotypes. The same conclusion holds for the correlation as well. In
addition, the percentage of missing data can also affect the imputation accuracy in a
family study. Unlike a population-based study in which only the missing sample’s
collected phenotypes are leveraged, the relatives of the missing sample also contribute to
the imputed values in a family study. A large percentage of missing data can decrease the
number of relatives contributing, therefore percentage of missing data is a factor of
imputation accuracy in family studies.
3.2.8 Simulation Evaluation for Single Variant Test
The goals of the simulation study are 1) to examine and compare our approximated NCP
derivation and the NCP derived under NMM for the single variant test using unrelated
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samples; 2) to evaluate imputation power and type-I error rate under different conditions
using family data and 3) to examine imputation accuracy with and without using family
structure in the imputation.
To achieve the first goal, a locus with MAF = 0.2 is generated using a binomial
distribution. We simulate three phenotypes for each of 2000 unrelated individuals.
Because the test statistic and NCP (under NMM assumption) in the original PhenIMP
paper were derived with standardized data, we also standardize our simulated phenotypes
and genotypes for comparison. We assume that the polygenic and environmental
covariance matrices are






which imply that each phenotype has a heritability of 50% and the pair-wise correlations
between phenotypes are set to ±0.5. We assume that the first phenotype has a missing
percentage of 20%, 50% or 80%, and the second and third phenotypes are complete. The
missing values in the first phenotype are imputed using the second phenotype alone, the
third phenotype alone, and the second and the third phenotypes together. The phenotypic
variances of the three phenotypes explained by the single variant (R2) are set to 2%, 1%
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From the above NCP derivation, it is easy to see that the product of the expected effect
size of the phenotypes and the pair-wise correlations is the factor affecting the statistical
power of the single variant test. Therefore, we fix the direction of the effect sizes (all > 0)
and vary the sign of the pair-wise correlations in order to examine every possible
combination in the simulation. The analysis to verify the NCP derivation is implemented
in the R package seqMeta.
In order to evaluate our family-informed method, we generate 500 nuclear families
consisting of two parents and two children for a total sample size of 2000. For type-I error
rate evaluation, we generate 50000 SNVs with MAF sampled from a uniform distribution
between 0.05 to 0.5. The genotypes for the parents are simulated first, then we randomly
assign one allele from each parent to generate the genotypes for their offspring. The
phenotype values are simulated from the MVN distribution previously described. Note
that the kinship matrix Φ is computed from the pedigree and is not equal to the identity
matrix. We assign different constant mean levels for different phenotypes, so none of the
50000 SNVs are associated with either the phenotype of interest (Phe1) or the phenotypes
we use to impute (Phe2 and Phe3). Missing percentage is set to 20%, 50% and 80%. The
simulations are repeated 3000 times for a total of 150 million SNVs and we examine
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type-I error rate at significance levels of 0.05, 1×10−3 and 1×10−5.
To evaluate power, we use the same family settings (500 nuclear families for a total of
2000 individuals). A single variant is tested and the phenotype values are generated from
the MVN distribution using the same kinship matrix Φ as above. The mean level of the
MVN distribution is computed using the same settings (MAF, β , R2 and correlation
between phenotypes) as the simulation for NCP examination. The association test for
type-I error rate and power evalutaion is performed using a linear mixed effects model in
the software EMMAX.
The third goal of the simulation is to examine imputation accuracy under different
conditions. We use family data that are generated for power evaluation. The phenotype
pair-wise correlations are restricted to be positive. The missing phenotype values are
imputed using our family-informed method and PhenIMP which ignores the family
structure. We also examine the effect of different missing percentage (20%, 50% and
80%) on imputation accuracy. Both correlation and MSE between the true and imputed
values are computed as measurements of imputation accuracy.
3.2.9 Application of 2 Hour Glucose in FHS
FHS is a longitudinal study initiated in the year of 1948. It has made significant
contribution in identifying the risk factors for CVD, as well as other diseases including
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Type-2 Diabetes (T2D). FHS consists of three generations and 14428 individuals from
Framingham, MA: the original cohort, the offspring cohort and the third generation cohort
(Gen3). Fasting glucose (FG) and 2 hour glucose (2hrglu) were obtained in FHS
Offspring and Gen3 Cohorts with genotypes available in SNP Health Association
Resource (SHARe). These two phenotypes were collected in exam 5 for the Offspring
Cohort and exam 2 in the Gen3 Cohort. There are 173 individuals with missing 2 hour
glucose values and the FG values are complete. We exclude individuals with missing T2D
status or T2D cases. A linear mixed effects model with random intercept to account for
familial correlation is used with adjustment for age, age2, sex, BMI and cohort indicator to
test the association between five known loci (rs1260326, rs2877716, rs12243326 and
rs17271305 and rs10423928) and 2 hour glucose [40]. We impute the 173 missing 2 hour
glucose values using FG and test the association in the dataset of all observed 2 hour
glucose values, and the combined observed and imputed dataset. We also set different
percentages of individuals to missing and impute them using FG to examine the
performance of our method.
3.3 Results
We first examine the NCP approximation for single variant test by comparing the
empirical power with the approximated theoretical power (Table 3.1, 3.2, 3.3). Two
datasets are used in the evaluation: the imputed values alone (Imp), and the combined
imputed and observed data (Imp+Obs). When using one phenotype (either phenotype 2 or
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3) to impute the missing phenotype 1 values, we vary the direction of the correlation
(positive and negative) between the two phenotypes. And when using both phenotypes in
the imputation, we examine all 8 combinations of different pair-wise correlation
directions. Note that because the data are standardized, the NCP of the pooled data is
equivalent to the NCP of the Stouffer’s signed Z-score method with optimal weights.
Under the assumption of NMM, the NCP is determined by the effect size of phenotype 1
and the correlation between the phenotypes, so we expect to see the same NCP for using
phenotypes 2 and 3 because the correlation between phenotype 2 and phenotype 1 is equal
to the correlation between phenotype 3 and phenotype 1.
The results show that the empirical power is very similar to the theoretical power
computed using our theoretical approximation, with random fluctuation in an acceptable
range in all situations. The theoretical power computed using NMM does not take the
direction of pair-wise phenotype correlations into consideration and hence can not predict
the statistical power correctly.
Another interesting finding is that the power of Imp+Obs is even lower than the power of
Imp in some cases. For example, in the last row of Table 3.1 (pair-wise correlation
between phenotypes is labeled as “- - -”), the power of the imputed data is 22.2%, but the
power for the combined imputed and observed data is only 18%. This is because the effect
size of the observed data is in an opposite direction of the effect size of the imputed data
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which is determined by the pair-wise correlation between phenotypes and the direction of
the effect sizes of the phenotypes included in the imputation (phenotypes 2 and 3 in this
example). The power of Imp+Obs is lower than the power of Imp because the effect sizes
of Imp and Obs compensate for each other in Imp+Obs.
We examine the type-I error rate of family data in the imputed only and the combined
imputed and observed datasets under different missing percentages. All of the type-I error
rates are correctly controlled (Table 3.4).
Next, we compare the empirical power of the combined and imputed family data vs. the
power of the incomplete data (Table 3.5). When using one additional phenotype, either
Phe2 or Phe3, imputation can boost power when the sign of ϕ12 (ϕ13) is the same as the
sign of β1×β2 (β1×β3), and it reduces power when they are not the same. When
imputing the missing values from two additional phenotypes, the power is determined by
the signs of β1×β2 and β1×β3. If ϕ12 has the same sign as β1×β2 and ϕ13 has the same
sign as β1×β3, we will see a power boost, otherwise there is a loss in power. These
conclusions also hold in simulations with unrelated samples and can be verified using the
NCP derived in the theoretical power approximation.
We then evaluate the effect of incorporating family structure information in the imputation
on imputation accuracy when samples are related (Tables 3.6, 3.7). As expected, the
correlation is higher and the MSE is lower when taking the family structure into account.


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.5: Power evaluation for the combined observed and imputed family data
Phen. Corr. Missing Percentage
P= 1×10−5 ϕ12 ϕ13 ϕ23 20% 50% 80%
Complete 95.9% 96.6% 96.2%
Incomplete 87.6% 49.0% 5.4%
Phe2
+ 91.3% 77.7% 51.7%
- 73.6% 12.4% 0%
Phe3
+ 90.7% 75.6% 43.3%
- 70.4% 11.0% 1.4%
Phe2 + Phe3
+ + + 92.2% 82.8% 61.4%
+ + - 97.2% 99.2% 100%
+ - + 84.8% 35.7% 1.0%
+ - - 83.0% 40.1% 3.6%
- + + 83.2% 25.5% 0%
- + - 82.4% 38.0% 4.6%
- - + 67.6% 8.8% 2.0%
- - - 55.4% 0% 2.3%
imputation. As expected, analyses with families of 2 parents and 4 offsprings have a better
imputation accuracy than families with 2 parents and 2 offsprings. This is because
families with more relatives provide more information that can be exploited in the
imputation. Missing percentage affects the imputation accuracy of family data because
fewer family members contribute to the imputation under a higher missing percentage. In
addition, the effect size of the SNV on the phenotype does not affect the imputation
accuracy. This is verified by comparing correlation and MSE between using Phe2 and
Phe3, where the SNV has a bigger effect on Phe2.
The FHS glycemic dataset has 5,830 individuals from the Offspring and Gen3 Cohorts.
FG is observed on every individual, while 2 hour glucose has 173 missing values. The
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Table 3.6: Imputation accuracy of family data (2 parents + 2 offsprings)
Missing Percentage Family structure
No Yes No Yes
Correlation MSE
Phe2
20% 0.50 0.58 0.75 0.67
50% 0.50 0.55 0.75 0.70
80% 0.50 0.52 0.75 0.73
Phe3
20% 0.51 0.58 0.75 0.66
50% 0.50 0.55 0.75 0.70
80% 0.51 0.52 0.74 0.73
Phe2 + Phe3
20% 0.58 0.64 0.66 0.59
50% 0.58 0.62 0.66 0.62
80% 0.58 0.60 0.67 0.65
‘No’: ignoring family structure in the imputation; ‘Yes’: including family structure in the
imputation.
Table 3.7: Imputation accuracy of family data (2 parents + 4 offsprings)
Missing Percentage Family structure
No Yes No Yes
Correlation MSE
Phe2
20% 0.50 0.60 0.75 0.63
50% 0.50 0.57 0.75 0.67
80% 0.50 0.53 0.75 0.72
Phe3
20% 0.50 0.60 0.74 0.63
50% 0.51 0.57 0.74 0.67
80% 0.51 0.54 0.74 0.71
Phe2 + Phe3
20% 0.58 0.66 0.66 0.56
50% 0.58 0.64 0.66 0.60
80% 0.58 0.61 0.66 0.64
‘No’: ignoring family structure in the imputation; ‘Yes’: including family structure in the
imputation.
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Table 3.8: Association tests results of FG and 2 hour glucose in FHS
SNV FG 2hrglu
β SE P β SE P
rs1260326 -0.632 0.158 6.3 ×10−5 0.920 0.503 0.068
rs2877716 -0.521 0.186 5.2 ×10−3 -1.659 0.594 5.2 ×10−3
rs12243326 0.418 0.173 0.016 1.658 0.552 2.7 ×10−3
rs17271305 -0.133 0.162 0.41 1.020 0.516 0.048
rs10423928 -0.284 0.199 0.63 2.910 0.634 4.5 ×10−6
Bold: expected to see an increase in power.
sample correlation between FG and 2 hour glucose is 0.39. We select 5 loci previously
identified to be associated with 2 hour glucose [40]. We first test the association of these 5
loci in our data. Four of the 5 loci (rs2877716, rs12243326, rs17271305 and rs10423928)
are significantly associated with 2 hour glucose, with a P-value less than 0.05, and 1 locus
(rs1260326) is just slightly above the 0.05 threshold (Table 3.8). Based on the
approximated NCP derivation and the simulation results above, we expect a more
significant association test result on rs2877716 and rs12243326 after imputation because
these 2 loci are associated with FG and the effect sizes are in the same direction as their
effect sizes on 2 hour glucose. For the other 3 loci, their effect sizes on FG and 2 hour
glucose are in different directions, hence we do not expect to see a more significant result
by imputing from FG.
We refer to the dataset of all 5,830 individuals as “All” and the dataset of the 5,657
individuals with no missing FG and 2 hour glucose as “Obs”. We first assess the
association for the 5 loci in “Obs”. Then the 173 missing values of 2 hour glucose in “All”
are imputed using FG and the association analysis is repeated. To fully examine our
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method, we also randomly set 3%, 10%, 25%, 50% and 80% 2 hour glucose values in
“Obs” to missing, then impute the missing values using FG. We then test the 5 loci in both
the incomplete dataset in which missing values are removed, referred to as “(1-K%) Obs”,
and the combined incomplete and imputed dataset, referred to as “(1-K%) Obs + K%
Imp”, where K% is the missing percentage. We repeat this process 200 times and report
the median of the P-values from the 200 iterations.
For rs1260326, rs17271305 and rs10423928, imputation from FG does not improve the
association test results: P-values from “Obs” are more significant than “All”, and the
incomplete dataset “(1-K%) Obs” outperforms the combined dataset “(1-K%) Obs + K%
Imp” for all 5 missing percentage scenarios (Table 3.9). This is not surprising because
their effects on FG and 2 hour glucose are in different directions. The imputation
improves significance for rs2877716 as expected. For rs12243326, we find a more
significant P-value when the missing percentage is over 25%. Although the imputation
does not improve the significance of P-values when the missing percentages are below
10%, P-values before and after imputation are the same or very close. As expected, a
larger missing percentage can cause the loss in power (a less significant P-value) in both












































































































































































































































































































































































































We extended PhenIMP to leverage information contained not only in correlated
phenotypes but also family structure. We showed that taking the family structure into
consideration could improve imputation accuracy. In addition, we investigated the
situations where our method can increase power and the situations we do not expect power
gains from imputation. We also derived the theoretical NCP for PhenIMP because the
NCP based on NMM can not accurately predict power in the single variant association
test. In the analysis of the combined observed and imputed data, we found that the pooled
analysis is equivalent to the meta-analysis of Z score when the data are standardized.
Our method uses the same MVN distribution model as PhenIMP and PHENIX. These
three methods also share the same underlying assumption of pleiotropy and hence may
lose power when this assumption does not hold [38]. We performed the first investigation
of imputation accuracy and power, to our knowledge, by extensive simulations and we
determined factors that could affect imputation accuracy and power. Our conclusions can
also be generalized to PhenIMP and PHENIX because the three methods have the same
assumption of MVN distribution.
The model we propose can impute missing values on multiple phenotypes at once, hence
we do not need to repeat the same imputation process for each missing phenotype. We
estimate the genetic and environmental variance components through MLE, without the
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need to collect pilot data prior to the analysis. However, we acknowledge that when the
number of observed individuals is too small (high missing percentage), it might be better
to use a pilot dataset to estimate the pair-wise phenotype correlations because the MLE
may provide a poor estimate of the true value. Through simulation, we showed that MLE
worked well even under an 80% missing percentage.
Intuitively, with more phenotypes being used in the imputation, we would expect a better
imputation accuracy because more phenotypes contain more information. However, based
on our simulation results, the number of phenotypes and the pair-wise correlation between
phenotypes are the most important factors that determine the accuracy of the imputation.
The sign of effect sizes and the correlation between phenotypes determine whether or not
the power can be improved after imputation. Including phenotypes with different
directions of the SNV effect might decrease power. We suggest to start with one or two
additional phenotypes because it’s easy to keep track of the change in NCP when the
number of phenotypes is small.
The analysis of the combined observed and imputed data needs to be performed
cautiously. Because the imputed data have a biased effect size estimate and a different
variance than the observed data, the effect size estimates from the combined dataset are
not accurate. Here we suggest to use the P-value from the combined dataset since the
imputation can improve power to detect the association and use the effect size estimate
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from the observed dataset because it is not subject to the bias due to imputation.
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Chapter 4 Extension of a Phenotype Imputation Approach to Variant-Set Tests
4.1 Introduction
Common variants found to be associated with a trait and identified by GWAS can only
explain a small proportion of heritability. For example, although Alzheimer’s Disease has
a heritability of h2 = 0.58−0.79 [41], not much heritability can be explained by the major
genetic risk factor APOE [42, 43] gene and other loci identified in European ancestry
individuals [44, 45, 46]. It is still not clear how to explain the missing heritability that can
not be accounted for by common variants detected so far. With the huge fall in genome
sequencing costs, more focus has been placed on rare variants to try to explain the missing
heritability. Because single-variant tests for rare variants remain challenging due to the
lack of power to detect associations, several variant-set tests have been developed to
address the issue of low power of rare variant tests.
One class of the variant-set test is burden tests. In burden tests, the genotypes of single
variants in the region are collapsed into an aggregated score. A regression model is then
fitted with the aggregated score as the independent variable and the phenotype as the
dependent variable. Burden tests are most powerful when all variants within the region
have the same direction of effect and the proportion of causal SNVs is high. Alternatively,
SKAT uses a variance component model and retains power when the variants have
different directions of effect. It has been proven to be more powerful than burden tests
when variants have different directions of effect. The SKAT statistic is equivalent to the
weighted sum of the score statistic for single variants, which is very useful for
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meta-analysis.
In the previous chapter, we developed a family-informed phenotype imputation approach
and we showed that our approach can improve statistical power in single variant
association tests under certain situations. But the performance of our method in variant-set
tests has not been evaluated. Intuitively, the situation is more complicated because
different SNVs in the same region could affect the phenotype in different directions and
not all SNVs are causal. Hence, there is a need to further investigate the performance of
our phenotype imputation approach in variant-set tests.
In this chapter, we first derive an approximation to the theoretical power for two
variant-set tests, burden test and SKAT, in unrelated samples. Then we use simulation to
evaluate our theoretical power approximation, examine type-I error rate and investigate
situations where our method can boost power and situations where imputation can not
improve statistical significance in unrelated and family samples, respectively. Lastly, we
use a real data example of FHS to validate our findings in simulation study.
4.2 Methods
4.2.1 Power of Burden Test
We derive an analytical approximation to compute power for two popular variant-set tests,
burden test and SKAT, when the study subjects are unrelated. We focus on the situation in
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which the combined observed and imputed data are analyzed jointly. The derivation using
the imputed data alone is similar and requires fewer steps.
In a burden test, one way to compute power theoretically is consider the burden score as a
single variant. When the aggregated variants have a cumulative minor allele frequency
(cMAF), say 5%, then the power is equivalent to a single variant test with the same MAF.
So we can directly use the non-centrality parameter (NCP) for single variant test we
derived in chapter 3 to compute power for burden test. However, using this method, we
assume that all single variants within the gene have the same effect size, which is not true
in most cases. Here we show an analytical approach to compute power which allows
different effect size for each variant.
We assume y is a length n vector of the observed and imputed phenotype 1 values, and we
divide y into two parts: yo the length n(1− r) vector of the n(1− r) samples with the
observed phenotype 1 values and ym the length nr vector of the nr imputed samples.
Similarly, we assume s is a vector of the aggregated burden for n individuals and we
divide s into so the burden scores for observed individuals and sm the burden scores for
imputed individuals. In addition, we assume φ is a l× l correlation matrix of the l SNVs
within the gene, where φi j describes the correlation between SNV i and SNV j, and w j is
the weight for SNV j. The burden score vector so and sm can be computed as ∑li=1 wixo,i
and ∑li=1 wixm,i, where xo,i and xm,i are the genotype vector for SNV i on the n(1− r)
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observed and nr imputed samples, respectively.
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n(1− r)[∑li=1 wiφi,1, . . . ,∑li=1 wiφi,l]β1
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nr[∑li=1 wiφi,1, . . . ,∑
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oo Σom
n(1− r)∑li=1 ∑lj=1 wiw jφi, j +nr ∑li=1 ∑lj=1 wiw jφi, j
=
[∑li=1 wiφi,1, . . . ,∑
l





j=1 wiw jφi, j
(4.1)
The variance of the beta estimate can be computed as
Var(β̂ ) = σ2(sT s)−1









Hence the NCP of the test statistic of Burden test can be written as
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√
n[∑li=1 wiφi,1, . . . ,∑
l
i=1 wiφi,l]((1− r)β1 + r[β2, . . . ,βK]Σ−1oo Σom)√
((1− r)+ rΣmoΣ−1oo Σom)∑li=1 ∑lj=1 wiw jφi, j
(4.3)
4.2.2 Power of SKAT
We assume that the linear model relating the variants in a region to the phenotype is
yi = γ0 +Ciγ +Giβ , where yi is the ith element of the phenotype vector y, γ0 is the
intercept, Ci is the ith row of the covariates matrix C, γ is the vector of regression
coefficients for the covariates, Gi is the ith row of the n× l genotype matrix G of l SNVs
and β is the length l vector of regression coefficients for the l SNVs.
The SKAT statistic has the form of Q = (y− µ̂)′K(y− µ̂), where µ̂ = γ̂0 +Cγ̂ , γ̂0 and γ̂
are the estimated regression coefficients under the null, K = GWG′ and
W = diag(w(m̂1), · · · ,w(m̂l)) with m̂ j being the MAF for SNV j.
Unlike SKAT with complete data, in which y− µ̂ has In×nσ21 as asymptotic covariance
matrix, the combined observed and imputed phenotype vector y− µ̂ follows MVN






We first find the orthonormal matrix U that converts Σ1/2KΣ1/2 to its diagonal form
diag(λ1, . . . ,λn)=UΣ1/2KΣ1/2UT . Then let Z =UΣ−1/2(y− µ̂) which follows a MVN
distribution with mean µz =UΣ−1/2µβ and covariance matrix = In×n. Now we can rewrite
Q as a weighted sum of Chi-square variables






1 (δ j) (4.5)
where δ j = µ2z j, µz j is the jth element of µz. Using the method proposed by Liu et al. [26],
we approximate the distribution of Q using a non-central Chi-square variable. Following
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G2(β2, . . . ,βK)Σ−1oo Σom
, βk is a length l vector which contains the effect
sizes of l SNVs on phenotype k, G1 is an n(1− r)× l genotype matrix for the n(1− r)
observed samples and G2 is an nr× l genotype matrix for the nr samples with missing















































G2(β2, . . . ,βK)Σ−1oo Σom

= GT1 G1β1 +G
T
2 G2(β2, . . . ,βK)Σ
−1
oo Σom
= n(1− r)φβ1 +nrφ(β2, . . . ,βK)Σ−1oo Σom
(4.9)
where φ is a l× l matrix describing the covariance between the l SNVs. If the genotypes
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are standardized, we can use the LD matrix as φ . We then follow the steps described in
[33] to approximate the theoretical power for SKAT.
4.2.3 Simulation
We use simulation to examine our theoretical power derivation for burden test and SKAT,
and evaluate type-I error rate and power of these two variant-set tests for imputed
phenotype values.
To generate single variants in the same region with LD, we first generate continuous latent
variables from a MVN distribution, which has an order one autoregressive model with
ρ = 0.8 as the covariance matrix. Then for each variant, we assign 2 as the additive
genotype to individuals with the latent variable below the p2 quantile, 0 when the latent
variable is above the (1− p)2 quantile and 1 for the rest, where p is the MAF of the
variant.
In all simulations, we generate 2000 unrelated individuals and 2000 related individuals
from 500 nuclear families with two parents and two children. When generating the related
individuals, we first use the method described above to generate genotypes for all parents,
then randomly assign one allele from each parent to generate the genotypes for the
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children.
We first compare the empirical power from simulations to the approximated theoretical
power. We simulate 5 single variants with MAF = 0.01, 0.015, 0.02, 0.025 and 0.03,
respectively. The effect size of each single variant is determined by
√
R2
2p(1−p) , where R
2 is
the proportion of phenotypic variance explained by the variant and p is the MAF. We set
R2 to 0.1%, 0.1%, 0.5%, 0.2% and 0.2% for phenotype 1 (Phe1), 0.005%, 0, 0.3%, 0 and 0
for phenotype 2 (Phe2) and 0, 0, 0.1%, 0.2% and 0.1% for phenotype 3 (Phe3). All of the
effect sizes are positive. We use the Wu weights (dbeta(1,25)) in SKAT [27] and the
Madsen and Browning weights (
√
1
ma f (1−ma f )) in Burden test.
To evaluate type-I error rate and power under different conditions, we include 20 single
variants with MAF randomly sampled from a uniform distribution between 0.002 and
0.05. Three phenotypes are simulated: one phenotype of interest (Phe1) and two
additional phenotypes (Phe2 and Phe3). The pair-wise correlation between them is set to
±0.5. We vary the missing percentage from 20% to 50% and evaluate type-I error rate and
power using unrelated and family data, respectively. In the type-I error rate evaluation,
none of the 20 SNVs are associated with the phenotypes. When evaluating power, we set
the absolute value of the effect size for each SNV to c|log10MAF |, where c = 0.2, 0.1 and
0.05 for Phe1, Phe2 and Phe3, respectively. We also set the proportion of causal variants
to 20%, 50% and 80% and vary the percentage of SNVs with the same directions of effect
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from 100% to 50%.
4.2.4 Application of 2 Hour Glucose in FHS
The Framingham Heart study began in 1948 with participants from the town of
Framingham, MA. It now has 14428 participants from 3 generations: Original, Offspring
and the 3rd generation (Gen3). We apply our method on Offspring and Gen3 participants
with glycemic traits available. We select 4 genes (G6PC2, GCKR, GLP1R and VPS13C)
which contain at least one previously identified variant associated with 2 hour glucose or
fasting glucose (FG) in [47, 48]. We perform SKAT (Wu weights) on individuals from the
Offspring and Gen3 cohorts in FHS with adjustment of age, age2, BMI, cohort indicator
and the top 10 PCs. Diabetic individuals are excluded from the analysis. The variant-set
tests are restricted to nonsynonymous variants with MAF < 0.05 in exome-chip genotype
set [18]. Among the 5627 individuals with available genotype data, 164 have missing 2
hour glucose values while FG is complete. Missing values are imputed using our
family-informed imputation approach. We perform variant-set association tests on 5463
individuals with observed 2 hour glucose values, and the combined dataset of the 5463
observed and 164 imputed individuals. In addition, we randomly select 20% and 50% of
the 5463 individuals and set their 2 hour glucose values to missing. We then impute them
and test the association using the observed, and the combined observed and imputed
datasets to evaluate the performance under different missing percentages.
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Table 4.1: Power of combined observed and imputed data for unrelated samples with 20%
missing percentage in variant-set tests.
Power Phen Corr Burden SKAT
α = 1×10−5 ϕ12 ϕ13 ϕ23 Empirical Theoretical Empirical Theoretical
Phe2
+ 95.2% 95.4% 96.5% 97.2%
- 87.2% 86.8% 89.8% 91.6%
Phe3
+ 96.0% 96.6% 97.1% 97.8%
- 84.4% 85.0% 88.4% 89.7%
Phe2 + Phe3
+ + + 96.2% 96.6% 97.1% 97.8%
+ + - 98.0% 98.6% 98.7% 99.1%
+ - + 78.8% 79.0% 82.7% 83.5%
+ - - 92.2% 92.4% 92.5% 93.4%
- + + 87.2% 88.2% 88.8% 91.9%
- + - 93.6% 93.6% 93.8% 95.2%
- - + 86.4% 85.8% 86.0% 87.7%
- - - 51.6% 53.0% 47.5% 49.7%
4.3 Results
We first examine our approach to compute theoretical power for burden test and SKAT
under missing percentage of 20% (Table 4.1) and 50% (Table 4.2). The empirical power is
similar to the approximated theoretical power in all cases indicating that our power
approximation for SKAT and burden tests can be used to predict statistical power when
designing a genetic association study.
Next, we examine the type-I error rate in unrelated (Table 4.3) and family data (Table 4.4).
The missing phenotype values are imputed using either one (Phe2) or two (Phe2 + Phe3)
additional phenotypes and we evaluate the type-I error rate in the imputed dataset, and the
combined observed and imputed dataset, respectively, under α level of 0.05, 10−3 and
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Table 4.2: Power of combined observed and imputed data for unrelated samples with 50%
missing percentage in variant-set tests.
Power Phen Corr Burden SKAT
α = 1×10−5 ϕ12 ϕ13 ϕ23 Empirical Theoretical Empirical Theoretical
Phe2
+ 74.6% 76.5% 75.2% 78.7%
- 24.2% 21.3% 22.8% 22.9%
Phe3
+ 84.5% 82.6% 85.3% 87.1%
- 15.4% 9.2% 15.6% 14.3%
Phe2 + Phe3
+ + + 83.2% 83.0% 83.8% 86.3%
+ + - 97.7% 96.9% 97.9% 98.1%
+ - + 9.0% 5.6% 9.6% 9.0%
+ - - 36.8% 36.3% 37.6% 37.3%
- + + 34.5% 26.2% 38.5% 38.4%
- + - 50.6% 47.2% 50.6% 54.3%
- - + 13.0% 8.5% 12.6% 9.3%
- - - 0.2% 0% 0.2% 0%
10−5. All type-I error rates are correctly controlled for burden test and SKAT.
To investigate situations where our imputation approach can have a gain in power, we vary
the sign of phenotype correlation, proportion of causal variants, percentage of variants
with the same direction of effect and missing percentages in the simulation (Tables 4.5,
4.6, 4.7, 4.8). As expected, a high missing percentage can lead to a loss in power. Burden
tests perform well when the effects of the variants are in the same direction and it almost
has no power in the situation where 50% SNVs have a positive effect and 50% SNVs have
a negative effect. Meanwhile, SKAT is powerful in both situations. The percentage of
causal variants also affects power: the larger the percentage is, the higher the power we
achieve. Our simulations assume that each variant affects the three phenotypes in the same
direction, that is β1,β2,β3 all > 0 or < 0, and the directions can be different for different
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Table 4.3: Relative Type-I error rate of unrelated data in variant-set tests.
Test r Type-I error rate
α Level 0.05 10−3 10−5
Imp Imp+Obs Imp Imp+Obs Imp Imp+Obs
Phe2
Burden
20% 1.00 1.00 1.00 1.01 1.02 1.01
50% 0.97 0.99 0.98 1.00 0.96 0.98
SKAT
20% 1.00 1.00 1.00 1.01 1.01 1.01
50% 0.99 1.00 0.98 0.98 1.00 1.01
Phe2 + Phe3
Burden
20% 1.00 1.01 1.00 1.01 1.00 1.01
50% 0.98 1.01 0.99 0.99 1.01 1.00
SKAT
20% 1.00 1.00 1.00 1.01 1.01 1.01
50% 1.00 0.98 1.02 1.01 1.01 1.00
Relative type-I error rate is the ratio between the empirical type-I error rate obtained from
simulation and the expect type-I error rate, which is the significance level. r represents the
missing percentage.
Table 4.4: Relative Type-I error rate of family data in variant-set tests.
Test r Type-I error rate
α Level 0.05 10−3 10−5
Imp Imp+Obs Imp Imp+Obs Imp Imp+Obs
Phe2
Burden
20% 0.98 1.02 0.99 1.01 0.98 1.01
50% 0.95 1.01 0.98 1.00 0.99 0.99
SKAT
20% 0.98 1.00 0.98 0.99 1.00 1.00
50% 0.99 1.00 1.01 1.01 0.97 0.98
Phe2 + Phe3
Burden
20% 0.93 0.99 0.92 0.97 0.89 0.97
50% 0.96 1.01 1.02 0.98 0.97 0.97
SKAT
20% 0.99 1.02 1.00 1.01 0.99 1.02
50% 1.00 0.99 0.98 1.02 1.03 1.01
Relative type-I error rate is the ratio between the empirical type-I error rate obtained from
simulation and the expect type-I error rate, which is the significance level. r represents the
missing percentage.
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variants (in the case of 50% > 0 and 50% < 0). Under this assumption, we obtain the
same conclusions as for single variant tests in simulations with different signs of
phenotype correlations. When using one additional phenotype, imputation can boost
power if the sign of ϕ12 (ϕ13) is the same as the sign of β1×β2 (β1×β3). When using two
additional phenotypes, power can be increased if ϕ12 has the same sign as β1×β2 and ϕ13
has the same sign as β1×β3.
In our real data application of FHS glycemic dataset, the estimated correlation between
FG and 2 hour glucose is 0.39. First, we test the association between the 4 genes (G6PC2,
GCKR, GLP1R and VPS13C) and FG or 2 hour glucose (Table 4.9). Two genes (G6PC2
and GLP1R) are associated with FG, but none of them are significant in the test of 2 hour
glucose. Hence, potentially we expect to see an increase of significance in genes G6PC2
and GLP1R. Next, we impute the 164 missing 2 hour glucose values using their observed
FG values. We refer to the 5463 individuals with observed 2 hour glucose values as “Obs”
and 5627 individuals with the observed and imputed 2 hour glucose values as “All”. In the
datasets where we randomly set samples from “Obs” missing, we use “(1-K%) Obs” to
represent the incomplete data (missing values are removed), and “(1-K%) Obs + K% Imp”
for the combined incomplete and imputed data, where K% is the missing percentage. Due
to the very low missing percentage in “All” (3%), the significance of the association test
results are similar between “All” and “Obs”. But when we use a higher missing
percentage (20% and 50%), most of the P-values in “(1-K%) Obs + K% Imp” are lower

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4.7: SKAT Power of family data (Imp+Obs) with 20% missing percentage in variant-
set tests
ϕ12 ϕ13 ϕ23 Power (%)
Phen Direction 100 / 0 50 / 50
Causal % 20% 50% 80% 20% 50% 80%
Complete 77.0 100 100 10.6 50.5 86.4
Incomplete 61.2 100 100 6.9 41.0 76.0
Phe2
+ 64.2 100 100 6.7 43.9 77.7
- 48.8 99.8 100 2.8 32.9 59.1
Phe3
+ 62.2 100 100 6.7 40.2 79.1
- 55.7 100 100 2.2 36.2 66.2
Phe2 + Phe3
+ + + 62.9 100 100 7.3 42.6 73.9
+ + - 70.5 100 100 5.0 53.8 79.9
+ - + 59.7 100 100 3.9 39.8 70.3
+ - - 63.4 100 100 3.9 38.4 66.0
- + + 46.0 100 100 2.2 30.4 56.8
- + - 54.8 100 100 3.4 33.7 63.8
- - + 48.3 100 100 2.2 31.5 62.3
- - - 33.5 100 100 0.6 18.8 50.5
Complete: all missing values are filled in with the true values. Incomplete: all missing
values are removed. α = 1×10−5.
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Table 4.8: SKAT Power of family data (Imp+Obs) with 50% missing percentage in variant-
set tests
ϕ12 ϕ13 ϕ23 Power (%)
Phen Direction 100 / 0 50 / 50
Causal % 20% 50% 80% 20% 50% 80%
Complete 77.7 100 100 7.3 52.1 81.1
Incomplete 32.3 100 100 2.2 20.8 42.6
Phe2
+ 45.6 100 100 3.4 27.1 53.3
- 9.4 93.8 100 0 3.4 16.5
Phe3
+ 34.5 100 100 2.6 20.2 42.4
- 13.7 98.8 100 0.2 7.5 19.4
Phe2 + Phe3
+ + + 42.4 100 100 3.2 25.3 49.0
+ + - 61.0 100 100 2.9 38.6 68.1
+ - + 32.4 99.6 100 0.6 16.1 33.3
+ - - 27.3 99.8 100 1.4 14.7 38.7
- + + 6.4 87.8 100 0 2.6 11.0
- + - 13.0 98.8 100 0.8 9.7 22.4
- - + 6.6 93.2 100 0.6 2.2 12.4
- - - 5.4 40.4 87.8 0 0.8 1.0
Complete: all missing values are filled in with the true values. Incomplete: all missing
values are removed. α = 1×10−5.
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Table 4.9: Variant-set association tests results of FG and 2 hour glucose in FHS
Gene nsnps P (FG) P (2hrglu)
G6PC2 9 0.03 0.93
GCKR 15 0.51 0.42
GLP1R 5 2.2×10−5 0.12
VPS13C 30 0.18 0.21
Table 4.10: Median P-values from FHS 2 hour glucose data in variant-set tests
Dataset Sample Size G6PC2 GCKR GLP1R VPS13C
Obs 5463 0.93 0.42 0.12 0.21
All 5627 0.91 0.41 0.09 0.22
80% Obs + 20% Imp 5463 0.82 0.52 0.08 0.19
80% Obs 4371 0.88 0.42 0.17 0.29
50% Obs + 50% Imp 5463 0.61 0.55 0.03 0.29
50% Obs 2732 0.76 0.61 0.36 0.35
imputation. GLP1R has P-values slightly above the α level of 0.05 in “All”. It shows an
improvement in significance compared with “Obs”.
4.4 Discussion
Because rare variants may play an important role in accounting for missing heritability
and understanding the biology of the diseases, variant-set association tests have received
significant efforts and powerful methods have been developed. However, variant-set tests
can still be affected by missingness in the phenotypic data and removing individuals with
missing observations can result in a decrease in statistical power. We extended our
family-informed phenotype imputation approach derived in Chapter 3 to variant-set
association test in genetic studies. The analytical approach to approximate theoretical
power for the burden test and SKAT when using the combined observed and imputed
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phenotype values was derived. Through extensive simulations, we also evaluated the cases
in which our family-informed approach can boost power. Finally, we used a real data
example in FHS to illustrate our findings.
By changing the covariance matrix of the phenotype vector and using a non-central
Chi-square variable to approximate the distribution of the test statistic, we are able to
approximate the power for SKAT theoretically. The simulation results showed that our
derivation can provide a very close approximation to the empirical power. We also derived
the NCP for burden test which allows different effect sizes for different single variants.
Because both the burden test and SKAT statistics can be written as a weighted sum of the
test statistics (or squared test statistics) from single-variant test, we found similar
conclusions on the performance of our method in variant-set tests. In addition to the
correlation between phenotypes and the direction of variant’s effect on the phenotypes,
proportion of causal variants and proportion of variants with the same direction of effect
also affect power in variant-set tests. In the application of FHS 2 hour glucose data, we
showed that when the association between the tested gene and the complete phenotype
(FG) was strong, our method can help improve significance of the imputed phenotype (2
hour glucose).
Variant-set association tests are more complicated than single variant test because each
variant within a gene can act differently, or even have opposite effects. In addition, the
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pleiotrophy assumption also needs to meet in order to improve statistical significance.
Because SKAT does not yield estimates of effect sizes, we do not need to run the
association test on observed data only in order to get an unbiased estimate of effect size as
in the single variant test. We chose to use the pooled data of the observed and imputed
phenotype values in simulations. Meta-analyzing these two datasets is another option and
needs to be examined in the future.
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Chapter 5 Summary and Future Work
In this dissertation, we investigated two issues in genetic association studies: population
stratification and missing data. Spurious association results can occur if the population
stratification is not corrected. With the increased use of WES genotype data, it is necessary
to understand the performance of population stratification adjustment using WES variants.
Missing data can cause insufficient statistical power to detect the associations. Even
though removing observations with missing values is the most common and easiest way to
handle missing data, it could potentially introduce bias when the missing pattern is not
missing completely at random (MCAR) and decrease power in association test.
In the first project, two population stratification adjustment methods, PCs and mixed
effects models, are examined using GWAS and WES variants, respectively. We found that
WES variants have very similar performance as GWAS variants in all evaluations. Hence,
computing PCs or GRM with WES variants can capture the population stratification
appropriately. When the phenotype is continuous, we observed that LMMs have a higher
power than PC-adjusted models for variants confounded by population stratification and
these two models perform similarly for variants not confounded by population
stratification. When the phenotype is binary, we observed that GLMMs with IBS kinship
matrix have inflated type-I error rate using either GWAS or WES variants and hence we
suggest to use the BN kinship matrix in GLMMs.
In the second project, we included information contained in family structure and
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correlated additional phenotypes in our phenotype imputation method. We derived an
approach to approximate the theoretical statistical power of the analysis using the
combined observed and imputed data. Based on this derivation of theoretical power and
simulations, we identified situations where the statistical significance can be improved
after imputation. We also showed that adding information from family structure can
increase the imputation accuracy and examined several factors that affect it. In our
simulation and real data application, we assumed that the data are missing completely at
random. Other missing mechanisms, missing at random (MAR) and missing not at
random (MNAR), would require the inclusion of information on other variables and hence
need future work.
In the third project, the performance of our family-informed phenotype imputation
approach was evaluated in variant-set tests. Approximation to theoretical power were
developed for the burden test and SKAT. We examined the performance of our method
under different correlation between phenotypes, percentages of missing data, proportion
of causal variants and variants with the same direction of effect size. Similar to the second
project, we also assumed that the missing mechanism is MCAR. Hence, the performance
of our method in MAR and MNAR needs further investigation.
89
Bibliography
[1] Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery.
American Journal of Human Genetics, 90(1): 7-24, 2012.
[2] Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, Yang J. 10
Years of GWAS Discovery: Biology, Function, and Translation. American Journal of
Human Genetics, 101(1): 5-22, 2017.
[3] Bush WS, Moore JH. Genome-Wide Association Studies. PLoS computational
biology, 8(12): e1002822.
[4] Patterson NJ, Price AL, Reich D. Population structure and eighenanlysis. PLoS
genetics, 2(12):e190, 2006
[5] Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal
components analysis corrects for stratification in genome-wide association studies.
Nature genetics, 38(8):904-909, 2006
[6] Devlin B, Roeder K. Genomic control for association studies. Biometrics,
55(4):997-1004, 1999
[7] Kang HM, Sul JH, Service SK, Zaitlen NA, Kong S, Freimer NB, Sabatti C, Eskin E.
Variance component model to account for sample structure in genome-wide
association studies. Nature genetics, 42(4):348-354, 2010
[8] Conomos MP, Thornton T. GENESIS: GENetic EStimation and Inference in
Structured samples (GENESIS): Statistical methods for analyzing genetic data from
samples with population structure and/or relatedness. R package version 2.0.1. 2016
[9] Pritchard J, Stephens M, Donnelly P. Inference of population structure using
multilocus genotype data. Genetics, 155:945-959, 2000
[10] Belkadi A, Pedergnana V, Cobat A, Itan Y, Vincent QB, Abhyankar A, Shang L,
Baghdadi JE, Bousfiha A, the Exome/Array Consortium, Alcais A, Boisson B,
Casanova J, Abel L. Whole-exome sequencing to analyze population structure,
parental inbreeding, and familial linkage. PNAS, 113(24):6713-8, 2016
[11] Gazal S, Gosset S, Verdura E, Bergametti F, Guey S, Babron MC, Tournier-Lasserve
E. Can whole-exome sequencing data be used for linkage analysis? Eur J Hum Genet,
24(4):581-6, 2016
[12] Smith KR, Bromhead CJ, Hildebrand MS, Shearer AE, Lockhart PJ, Najmabadi H,
Leventer RJ, McGillivray G, Amor DJ, Smith RJ, Bahlo M. Reducing the exome
search space for mendelian diseases using genetic linkage analysis of exome
genotypes. Genome Biol., 12(9):R85, 2011
[13] Kancheva D, Atkinson D, De Rijk P, Zimon M, Chamova T, Mitev V, Yaramis A,
Maria Fabrizi G, Topaloglu H, Tournev I, Parman Y, Battaloglu E, Estrada-Cuzcano
A, Jordanova A. Novel mutations in genes causing hereditary spastic paraplegia and
Charcot-Marie-Tooth neuropathy identified by an optimized protocol for
homozygosity mapping based on whole-exome sequencing. Genet Med., 18(6):600-7,
2016
90
[14] Eu-ahsunthornwattana J, Miller EN, Fakiola M, Wellcome Trust Case Control
Consortium 2, Jeronimo SMB, Blackwell JM, Cordell HJ. Comparison of Methods to
Account for Relatedness in Genome-Wide Association Studies with Family-Based
Data. PLoS Genet 10(7): e1004445, 2014
[15] The 1000 Genomes Project Consortium. A global reference for human genetic
variation. Nature, 526:68-74, 2015
[16] Su Z, Marchini J, Donnelly P. HAPGEN2: simulation of multiple disease SNPs.
Bioinformatics, 27(16):2304-2305, 2011
[17] Campbell CD, Ogburn EL, Lunetta KL et al. Demonstrating stratification in a
European American population. Nature Genetics, 37:868-872, 2005
[18] Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, Hansen M, Borecki
IB, Cupples LA, Fornage M et al. Best Practices and Joint Calling of the
HumanExome BeadChip: The CHARGE Consortium. PLoS One, 8(7): e68095, 2013
[19] International HapMap Consortium. The International HapMap Project. Nature,
426(6968):789-96, 2003.
[20] Collins AR. Linkage Disequilibrium and Association Mapping: Analysis and
Applications. Human Press, 2007.
[21] EPACTS: Efficient and Parallelizable Association Container Toolbox.
http://genome.sph.umich.edu/wiki/EPACTS
[22] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ et al. PLINK: a tool set for whole-genome association
and population-based linkage-analysis. American journal of human genetics,
81(3):559-575, 2007
[23] Almasy L, Blangero J. Multipoint quantitative trait linkage analysis in general
pedigrees. American journal of human genetics, 62:1198-122, 1998
[24] Price AL, Zaitlen NA, Reich D, Patterson N. New approaches to population
stratification in genome-wide association studies. Nat Rev Genet, 11(7): 459463, 2010
[25] Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL. Advantages and pitfalls
in the application of mixed-model association methods. Nat Genet, 46, 100106, 2014
[26] Liu H, Tang Y, Zhang HH. A new chi-square approximation to the distribution of
non-negative definite quadratic forms in non-central normal variables. Computational
Statistics and Data Analysis, 53:853-856, 2009
[27] Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for
sequencing data with the sequence kernel association test. American Journal of
Human Genetics, 89: 82-93, 2011
91
[28] Ionita-Laza I, Lee S, Makarov V, Buxbaum J, Lin X. Sequence kernel association
tests for the combined effect of rare and common variants. American Journal of
Human Genetics, 92: 841-853, 2013
[29] Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study
designs and statistical tests. American Journal of Human Genetics, 95L 5-23, 2014
[30] Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al..
Optimal unified approach for rare-variant association testing with application to
small-sample case-control whole-exome sequencing studies. American Journal of
Human Genetics, 91: 224-237, 2012
[31] Chen H, Meigs JB, Dupuis J. Sequence kernel association test for quantitative traits
in family samples. Genetic Epidemiology, 37(2): 196-204, 2013
[32] Chen H, Lumley T, Brody J, et al.. Sequence kernel association test for survival
traits. Genetic Epidemiology, 38(3): 191-197, 2014
[33] Lee S, Wu MC, Cai T, Li Y, Boehnke M, Lin X. Power and sample size calculations
for designing rare variant sequencing association studies. Harvard University
Technical Report, 2011
[34] Rubin DB. Multiple imputation for nonresponse in surveys. John Wiley & Sons, Inc,
1987
[35] Pasaniuc B, Zaitlen N, Shi H, Bhatia G, Gusev A, Pickrell J, Hirschhorn J, Strachan
DP, Patterson N, Price AL. Fast and accurate imputation of summary statistics
enhances evidence of functional enrichment. Bioinformatics, Volume 30, Issue 20, 15
October 2014, Pages 29062914
[36] Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K,
Wang D, Masys DR, Roden DM, Crawford DC. PheWAS: demonstrating the
feasibility of a phenome-wide scan to discover gene-disease associations.
Bioinformatics, Volumn 26, Issue 9, 1 May 2010, Pages 1205-1210
[37] Hormozdiari F, Kang EY, Bilow M, David EB, Vulpe C, McLachlan S, Lusis AJ,
Han B, Eskin E. Imputing phenotypes for Genome-wide Association Studies.
American journal of human genetics, 99: 89-103, 2016
[38] Dahl A, Iotchkova V, Baud A, Johansson A, Gyllensten U, Soranzo N, Mott R,
Kranis A, Marchini J. A multiple phenotype imputation method for genetic studies.
Nat Genet, 48(4): 466-472, 2016
[39] Dupuis J, Siegmund DO, Yakir B. A unified framework for linkage and association
analysis of quantitative traits. PNAS, 104(51): 20210-20215, 2007
[40] Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P,
Lyssenko V, Bouatia-Naji N, Dupuis J, et al. Genetic variation in GIPR influences the
glucose and insulin responses to an oral glucose challenge. Nat Genet,42(2):142-8,
2010
92
[41] Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A,
Pedersen NL. Role of genes and environments for explaining Alzheimer disease.
Archives of General Psychiatry, 63: 1168-174, 2006
[42] Corder EH, et al.. Gene dose of apolipoprotein E type 4 allele and the risk of
Alzheimers disease in late onset families. Science, 261:921923, 1993
[43] Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant
inheritance. Mol. Psychiatry, 16:903907, 2011
[44] Seshadri S, et al.. Genome-wide analysis of genetic loci associated with Alzheimer
disease. J. Am. Med. Assoc, 303:18321840, 2010
[45] Naj AC, et al.. Common variants at MS4A4/MS4A6E CD2AP CD33 and EPHA1
are associated with late-onset Alzheimers disease. Nat Genet, 43:436441, 2011
[46] Lambert JC, et al.. Meta-analysis of 74,046 individuals identifies 11 new
susceptibility loci for Alzheimers disease. Nat Genet, 45(12), 14521458, 2013
[47] Saxena R, et al.. Genetic variation in GIPR influences the glucose and insulin
responses to an oral glucose challenge. Nat Genet, 42, 142148, 2010
[48] Wessel J, et al.. Low-frequency and rare exome chip variants associate with fasting
glucose and type 2 diabetes susceptibility. Nat Commun, 6: 5897, 2015
93
94
95
